IRIS: Difference between revisions

From Opasnet
Jump to navigation Jump to search
(technical edits)
 
(6 intermediate revisions by 3 users not shown)
Line 41: Line 41:
  http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)
  http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)


===Oral RfDs===
{{defend|# |Tämähän alkaa olla oikein hyvä! Alla vielä muutamia kommentteja.|--[[User:Jouni|Jouni]] 20:34, 28 June 2012 (EEST)}}


Oral RfDs were scrapped as an example (chemical starting with A) on Jan 4, 2012.
* Tulokset on tässä kirjoitettu muotoon 3.4x10-3. Joko interpret-funktiota on päivitettävä siten, että se ymmärtää tämän, tai sitten kaikki näiden taulukoiden tulokset pitää muuttaa muotoon 3.4e-3 (jonka R ymmärtää oikein, kun käytetään as.numericia). Tuntuu, että interpretin päivitys olisi parempi vaihtoehto.
* Yksiköt pitäisi muuttaa tietokoneelle ymmärrettäväksi. Vaihtoehtoja: a) [[Unit conversions]] -sivulle lisätään kaikki tässä esiintyvät uudet yksiköt, niin että niille saadaan muunnosohjeet (esim. mg /kg-day &rarr; mg /kg /d tai per µg /m<sup>3</sup> &rarr; m3 /µg. b) Kaikki yksiköt tällä sivulla muutetaan tuohon standardimuotoon. Mikä tuntuisi järkevältä?
 
 
{{attack|# |Jos jossakin taulukossa joka rivillä on sama yksikkö, koko saraketta ei tarvita vaan riittää yksikön ilmoittaminen osoiterivillä.|--[[User:Jouni|Jouni]] 20:34, 28 June 2012 (EEST)}}


{{attack|# |Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä.|--[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}
{{attack|# |Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä.|--[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}
Line 52: Line 56:
|3 = --[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}
|3 = --[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}


<t2b index = "Substance,Observation type" locations = "CASRN,Critical Effact(s),Unit,Oral RfD,Type of RfD,Point of Departure(s)*,Overall Confidence,IRIS identifier" unit = "mg /kg-day">
==See also==
Acenaphthene|83-32-9| Hepatotoxicity|mg /kg-day|6 x10-2|NOAEL|175|Low|0442
Acenaphthylene|208-96-8|Not Assessed under the IRIS program||||||0443
Acephate|30560-19-1|Inhibition of brain ChE|mg /kg-day|4 x10-3|LEL|0.12|High|0354
Acetaldehyde|75-07-0|Not Assessed under the IRIS program||||||0290
Acetochlor|34256-82-1|Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males|mg /kg-day|2 x10-2|NOAEL|2 mg/kg-day|High|0521
Acetone|67-64-1|Nephropathy|mg /kg-day|0.9|NOAEL|900|Medium|0128
Acetonitrile|75-05-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0205
Acetophenone|98-86-2|General toxicity|mg /kg-day|1 x10-1|NOAEL|423|Low|0321
Acetyl chloride|75-36-5|Not Assessed under the IRIS program||||||0518
Acifluorfen, sodium|62476-59-9|Mortality and kidney lesions|mg /kg-day|1.3 x10-2|NOEL|1.25|Medium|0192
Acrolein|107-02-8|Decreased survival|mg /kg-day|5 x10-4|NOAEL|0.05|Medium/High|0364
Acrylamide|79-06-1|Degenerative nerve changes|mg /kg-day|0.002|HED (BMDL)|0.053|Medium/High|0286
Acrylic acid|79-10-7|Reduced pup weight|mg /kg-day|5 x10-1|NOAEL|53|High|0002
Acrylonitrile|107-13-1|Not Assessed under the IRIS program||||||0206
Adiponitrile|111-69-3|Not Assessed under the IRIS program||||||0515
Alachlor|15972-60-8|Hemosiderosis, hemolytic anemia|mg /kg-day|1 x10-2|NOAEL|1|High|0129
Alar|1596-84-5|No adverse effects|mg /kg-day|1.5 x10-1|NOEL|15|Low|0287
Aldicarb|116-06-3|Sweating as clinical sign of AChe inhibition (other effect: Clinical signs and symptoms of acetylcholinesterase inhibition including sweating, pinpoint pupils, leg weakness, and other effects Nausea, diarrhea, and other signs and symptoms)|mg /kg-day|1 x10-3|NOAEL|0.01|Medium|0003
Aldicarb sulfone|1646-88-4|Brain ChE inhibition in females|mg /kg-day|1 x10-3|NOAEL|0.11|Medium|0312
Aldrin|309-00-2|Liver toxicity|mg /kg-day|3 x10-5|LOAEL|0.025|Medium|0130
Ally|74223-64-6|Decreased body weight|mg /kg-day|2.5 x10-1|NOEL|25|High|0288
Allyl alcohol|107-18-6|Impaired renal function and increased liver and kidney weights|mg /kg-day|5 x10-3|NOEL|4.8|Low|0004
Allyl chloride|107-05-1|Not Assessed under the IRIS program||||||0387
Aluminum phosphide|20859-73-8|Body weight and clinical parameters|mg /kg-day|4 x10-4|NOAEL|0.043|Medium|0005
Amdro|67485-29-4|Increased organ weights|mg /kg-day|3 x10-4|NOEL|0.33|High|0207
Ametryn|834-12-8|Liver toxicity|mg /kg-day|9 x10-3|NOEL|8.6|Low|0208
4-Aminopyridine|504-24-5|Not Assessed under the IRIS program||||||0440
Amitraz|33089-61-1|Increased mean blood sugar concentration; slight hypothermia|mg /kg-day|2.5 x10-3|NOEL|0.25|Medium|0334
Ammonia|7664-41-7|Not Assessed under the IRIS program||||||0422
Ammonium acetate|631-61-8|Not Assessed under the IRIS program||||||0517
Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program||||||0516
Ammonium sulfamate|7773-06-0|Decrease in body weight|mg /kg-day|2 x10-1|NOEL|214.3|Low|0007
Aniline|62-53-3|Not Assessed under the IRIS program||||||0350
ortho-Anisidine|90-04-0|Not Assessed under the IRIS program||||||0610
Anthracene|120-12-7|No observed effects|mg /kg-day|3 x10-1|NOEL|1000|Low|0434
Antimony|7440-36-0|Longevity, blood glucose, and cholesterol|mg /kg-day|4 x10-4|LOAEL|0.35|Low|0006
Antimony trioxide|1309-64-4|Not Assessed under the IRIS program||||||0676
Apollo|74115-24-5|Liver effects; organ weight changes|mg /kg-day|1.3 x10-2|NOEL|1.25|High|0008
Aramite|140-57-8|Not Assessed under the IRIS program||||||0473
Aroclor 1016|12674-11-2|Reduced birth weights|mg /kg-day|7 x10-5|NOAEL|0.007|Medium|0462
Aroclor 1248|12672-29-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0649
Aroclor 1254|11097-69-1|Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes|mg /kg-day|2 x10-5|LOAEL|0.005|Medium|0389
Arsenic, inorganic|7440-38-2|Hyperpigmentation, keratosis and possible vascular complications|mg /kg-day|3 x10-4|NOAEL|0.0008|Medium|0278
Arsine|7784-42-1|Not Assessed under the IRIS program||||||0672
Asbestos|1332-21-4|Not Assessed under the IRIS program||||||0371
Assure|76578-14-8|Liver cell enlargement|mg /kg-day|9 x10-3|NOEL|0.9|High|0335
Asulam|3337-71-1|Lower ovarian weight, lower liver/body weight|mg /kg-day|5 x10-2|LEL|50|Medium|0284
Atrazine|1912-24-9|Decreased body weight gain (other effect: Cardiac toxicity and moderate-to-severe dilation of the right atrium)|mg /kg-day|3.5 x10-2|NOAEL|3.5|High|0209
Avermectin B1|65195-55-3|Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth|mg /kg-day|4 x10-4|NOEL|0.12|High|0381
Azobenzene|103-33-3|Not Assessed under the IRIS program||||||0351
Barium and Compounds|7440-39-3|Nephropathy|mg /kg-day|0.2|BMDL05|63|Medium|0010
Barium cyanide|542-62-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0009
Baygon|114-26-1|Mild cholinergic symptoms and RBD ChE inhibition|mg /kg-day|4 x10-3|LEL|0.36|Medium|0210
Bayleton|43121-43-3|Decreased body weight gain, erythrocyte count and hemoglobin level|mg /kg-day|3 x10-2|NOEL|2.5|High|0131
Baythroid|68359-37-5|Decreased body weights in males, inflammatory foci in kidneys of females|mg /kg-day|2.5 x10-2|NOEL|2.5|High|0132
Benefin|1861-40-1|Depressed erythrocyte counts|mg /kg-day|3 x10-1|NOAEL|25|Medium|0133
Benomyl|17804-35-2|Decreased pup weanling weights|mg /kg-day|5 x10-2|NOEL|5 mg/kg-day|High|0011
Bentazon (Basagran)|25057-89-0|Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs (other effect: Dose-related increase in red areas (presumed blood) in feces; coagulation defect)|mg /kg-day|3.0 x10-2|NOAEL (ADJ)|3.2|Medium|0134
Benz[a]anthracene|56-55-3|Not Assessed under the IRIS program||||||0454
Benzaldehyde|100-52-7|Forestomach lesions, kidney toxicity|mg /kg-day|1 x10-1|NOEL|143|Low|0332
Benzene|71-43-2|Decreased lymphocyte count|mg /kg-day|4.0 x10-3|BMDL|1.2|Medium|0276
Benzidine|92-87-5|Brain cell vacuolization; liver cell alterations in females|mg /kg-day|3 x10-3|LOAEL|2.7|Medium|0135
</t2b>
 
===Inhalation RfCs===
 
<t2b index = "Substance,Observation type" locations = "CASRN,Critical Effact(s),Unit,Inhalation RfC,Type of RfC,Point of Departure(s)*,Overall Confidence,IRIS identifier" unit = "mg /m<sup>3</sup>">
Acenaphthene|83-32-9|Not Assessed under the IRIS program.||||||
Acenaphthylene|208-96-8|Not Assessed under the IRIS program.||||||
Acephate|30560-19-1|Not Assessed under the IRIS program.||||||
Acetaldehyde|75-07-0|Degeneration of olfactory epithelium|mg /m<sup>3</sup>|9x10<sup>-3</sup>|NOAEL (HEC)|8.7|Low|0290
Acetochlor|34256-82-1|Not Assessed under the IRIS program.||||||
Acetone|67-64-1|Not Assessed under the IRIS program.||||||
Acetonitrile|75-05-8|Not Assessed under the IRIS program.||||||
Acetophenone|98-86-2|Mortality|mg /m<sup>3</sup>|6x10<sup>-2</sup>|NOAEL (HEC)|60|Medium|0205
Acetyl chloride|75-36-5|Not Assessed under the IRIS program.||||||
Acifluorfen, sodium|62476-59-9|Not Assessed under the IRIS program.||||||
Acrolein|107-02-8|Nasal lesions|mg /m<sup>3</sup>|2x10<sup>-5</sup>|LOAEL (HEC)|0.02|Medium|0364
Acrylamide|79-06-1|Degenerative nerve changes|mg /m<sup>3</sup>|0.006|HEC (BMDL)|0.18|Medium|0286
Acrylic acid|79-10-7|Degeneration of the nasal olfactory epithelium|mg /m<sup>3</sup>|1x10<sup>-3</sup>|LOAEL (HEC)|0.33|Medium|0002
Acrylonitrile|107-13-1|Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells|mg /m<sup>3</sup>|2x10<sup>-3</sup>|LOAEL (HEC)|1.9|Medium|0206
Adiponitrile|111-69-3|Not Assessed under the IRIS program.||||||
Alachlor|15972-60-8|Not Assessed under the IRIS program.||||||
Alar|1596-84-5|Not Assessed under the IRIS program.||||||
Aldicarb|116-06-3|Not Assessed under the IRIS program.||||||
Aldicarb sulfone|1646-88-4|Not Assessed under the IRIS program.||||||
Aldrin|309-00-2|Not Assessed under the IRIS program.||||||
Ally|74223-64-6|Not Assessed under the IRIS program.||||||
Allyl alcohol|107-18-6|Not Assessed under the IRIS program.||||||
Allyl chloride|107-05-1|Functional and histological peripheral neurotoxicity|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|3.6|Low|0387
Aluminum phosphide|20859-73-8|Not Assessed under the IRIS program.||||||
Amdro|67485-29-4|Not Assessed under the IRIS program.||||||
Ametryn|834-12-8|Not Assessed under the IRIS program.||||||
4-Aminopyridine|504-24-5|Not Assessed under the IRIS program.||||||
Amitraz|33089-61-1|Not Assessed under the IRIS program.||||||
Ammonia|7664-41-7|Not Assessed under the IRIS program.||||||
Ammonium acetate|631-61-8|Not Assessed under the IRIS program.||||||
Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program.||||||
Ammonium sulfamate|7773-06-0|Not Assessed under the IRIS program.||||||
Aniline|62-53-3|Lack of toxicity (other effect: Mild spleen toxicity )|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|3.4|Low|0350
ortho-Anisidine|90-04-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0610
Anthracene|120-12-7|Not Assessed under the IRIS program.||||||
Antimony|7440-36-0|Not Assessed under the IRIS program.||||||
Antimony trioxide|1309-64-4|Pulmonary toxicity, chronic interstitial inflammation|mg /m<sup>3</sup>|2x10<sup>-4</sup>|BMC<sub>10</sub> (HEC)|0.074|Medium|0676
Apollo|74115-24-5|Not Assessed under the IRIS program.||||||
Aramite|140-57-8|Not Assessed under the IRIS program.||||||
Aroclor 1016|12674-11-2|Not Assessed under the IRIS program.||||||
Aroclor 1248|12672-29-6|Not Assessed under the IRIS program.||||||
Aroclor 1254|11097-69-1|Not Assessed under the IRIS program.||||||
Arsenic, inorganic|7440-38-2|Not Assessed under the IRIS program.||||||
Arsine|7784-42-1|Increased hemolysis, abnormal RBC morphology, and increased spleen weight (other effect: Increased hemolysis, increased spleen weight, and impaired compensatory erythropoiesis)|mg /m<sup>3</sup>|5x10<sup>-5</sup>|NOAEL (HEC)|0.014|Medium|0672
Asbestos|1332-21-4|Not Assessed under the IRIS program.||||||
Assure|76578-14-8|Not Assessed under the IRIS program.||||||
Asulam|3337-71-1|Not Assessed under the IRIS program.||||||
Atrazine|1912-24-9|Not Assessed under the IRIS program.||||||
Avermectin B1|65195-55-3|Not Assessed under the IRIS program.||||||
Azobenzene|103-33-3|Not Assessed under the IRIS program.||||||
Barium and Compounds|7440-39-3|Not Assessed under the IRIS program.||||||
Barium cyanide|542-62-1|Not Assessed under the IRIS program.||||||
Baygon|114-26-1|Not Assessed under the IRIS program.||||||
Bayleton|43121-43-3|Not Assessed under the IRIS program.||||||
Baythroid|68359-37-5|Not Assessed under the IRIS program.||||||
Benefin|1861-40-1|Not Assessed under the IRIS program.||||||
Benomyl|17804-35-2|Not Assessed under the IRIS program.||||||
Bentazon (Basagran)|25057-89-0|Not Assessed under the IRIS program.||||||
Benz[a]anthracene|56-55-3|Not Assessed under the IRIS program.||||||
Benzaldehyde|100-52-7|Not Assessed under the IRIS program.||||||
Benzene|71-43-2|Decreased lymphocyte count|mg /m<sup>3</sup>|3x10<sup>-2</sup>|BMCL|8.2|Medium|0276
Benzidine|92-87-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0135
Benzo[a]pyrene (BaP)|50-32-8|Not Assessed under the IRIS program.||||||
Benzo[b]fluoranthene|205-99-2|Not Assessed under the IRIS program.||||||
Benzo[g,h,i]perylene|191-24-2|Not Assessed under the IRIS program.||||||
Benzo[k]fluoranthene|207-08-9|Not Assessed under the IRIS program.||||||
Benzoic acid|65-85-0|Not Assessed under the IRIS program.||||||
Benzotrichloride|98-07-7|Not Assessed under the IRIS program.||||||
Benzyl chloride|100-44-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0393
Beryllium and compounds|7440-41-7|Beryllium sensitization and progression to CBD|mg /m<sup>3</sup>|2x10<sup>-5</sup>|LOAEL (HEC)|0.0002|Medium|0012
Bidrin|141-66-2|Not Assessed under the IRIS program.||||||
Biphenthrin|82657-04-3|Not Assessed under the IRIS program.||||||
1,1-Biphenyl|92-52-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0013
Bis(2-chloro-1-methylethyl) ether|108-60-1|Not Assessed under the IRIS program.||||||
Bis(2-chloroethoxy)methane|111-91-1|Not Assessed under the IRIS program.||||||
Bis(chloroethyl)ether (BCEE)|111-44-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0137
Bis(chloromethyl)ether (BCME)|542-88-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0375
Bisphenol A.|80-05-7|Not Assessed under the IRIS program.||||||
Boron and Compounds|7440-42-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0410
Bromate|15541-45-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1002
Brominated dibenzofurans|NA|Not Assessed under the IRIS program.||||||
Bromobenzene|108-86-1|Hepatocellular cytomegaly in female B6C3F1 mice|mg /m<sup>3</sup>|6x10<sup>-2</sup>|BMCL<sub>10</sub> (HEC)|63|Low/Medium|1020
Bromochloromethane|74-97-5|Not Assessed under the IRIS program.||||||
Bromodichloromethane|75-27-4|Not Assessed under the IRIS program.||||||
p-Bromodiphenyl ether|101-55-3|Not Assessed under the IRIS program.||||||
Bromoform|75-25-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0214
Bromomethane|74-83-9|Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity|mg /m<sup>3</sup>|5x10<sup>-3</sup>|LOAEL (HEC)|0.48|High|0015
Bromotrichloromethane|75-62-7|Not Assessed under the IRIS program.||||||
Bromoxynil|1689-84-5|Not Assessed under the IRIS program.||||||
Bromoxynil octanoate|1689-99-2|Not Assessed under the IRIS program.||||||
1,3-Butadiene|106-99-0|Ovarian atrophy|mg /m<sup>3</sup>|2x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|1.98|Medium|0139
n-Butanol|71-36-3|Not Assessed under the IRIS program.||||||
Butyl benzyl phthalate|85-68-7|Not Assessed under the IRIS program.||||||
Butylate|2008-41-5|Not Assessed under the IRIS program.||||||
t-Butylchloride|507-20-0|Not Assessed under the IRIS program.||||||
Butylphthalyl butylglycolate (BPBG)|85-70-1|Not Assessed under the IRIS program.||||||
Cacodylic acid|75-60-5|Not Assessed under the IRIS program.||||||
Cadmium|7440-43-9|Not Assessed under the IRIS program.||||||
Calcium cyanide|592-01-8|Not Assessed under the IRIS program.||||||
Caprolactam|105-60-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0357
Captafol|2425-06-1|Not Assessed under the IRIS program.||||||
Captan|133-06-2|Not Assessed under the IRIS program.||||||
Carbaryl|63-25-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0019
Carbofuran|1563-66-2|Not Assessed under the IRIS program.||||||
Carbon disulfide|75-15-0|Peripheral nervous system dysfunction|mg /m<sup>3</sup>|7x10<sup>-1</sup>|BMC<sub>10</sub> (HEC)|19.7|Medium|0217
Carbon tetrachloride|56-23-5|Fatty changes in the liver|mg /m<sup>3</sup>|0.1|BMCL<sub>10</sub> (HEC)|14.3|Medium|0020
Carbonyl sulfide|463-58-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0617
Carbosulfan|55285-14-8|Not Assessed under the IRIS program.||||||
Carboxin|5234-68-4|Not Assessed under the IRIS program.||||||
Cerium Oxide and Cerium Compounds|1306-38-3|Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats|mg /m<sup>3</sup>|9x10<sup>-4</sup>|BMCL (HEC)|0.86|Low|1018
Chloral hydrate|302-17-0|Not Assessed under the IRIS program.||||||
Chloramben|133-90-4|Not Assessed under the IRIS program.||||||
Chlordane (Technical)|12789-03-6|Hepatic effects|mg /m<sup>3</sup>|7x10<sup>-4</sup>|NOAEL (HEC)|0.65|Low|0142
Chlordecone (Kepone)|143-50-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1017
Chlorimuron-ethyl|90982-32-4|Not Assessed under the IRIS program.||||||
Chlorine|7782-50-5|Not Assessed under the IRIS program.||||||
Chlorine cyanide|506-77-4|Not Assessed under the IRIS program.||||||
Chlorine dioxide|10049-04-4|Vascular congestion and peribronchial edema (other effect: Hemorrhagic alveoli and congested capillaries in the lungs)|mg /m<sup>3</sup>|2x10<sup>-4</sup>|LOAEL (HEC)|0.64|Low|0496
Chlorite (sodium salt)|7758-19-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0648
1-Chloro-1,1-difluoroethane|75-68-3|No adverse effects|mg /m<sup>3</sup>|5x10<sup>1</sup>|NOAEL (HEC)|14710|Medium|0661
2-Chloroacetophenone|532-27-4|Squamous hyperplasia of the nasal respiratory epithelium|mg /m<sup>3</sup>|3x10<sup>-5</sup>|LOAEL (HEC)|0.03|Low|0537
p-Chloroaniline|106-47-8|Not Assessed under the IRIS program.||||||
Chlorobenzene|108-90-7|Not Assessed under the IRIS program.||||||
Chlorobenzilate|510-15-6|Not Assessed under the IRIS program.||||||
1-Chlorobutane|109-69-3|Not Assessed under the IRIS program.||||||
2-Chlorobutane|78-86-4|Not Assessed under the IRIS program.||||||
Chlorocyclopentadiene|41851-50-7|Not Assessed under the IRIS program.||||||
Chlorodifluoromethane|75-45-6|Increased kidney, adrenal and pituitary weights (other effect: Reduced maternal weight gain)|mg /m<sup>3</sup>|5x10<sup>1</sup>|NOAEL (HEC)|5260|Medium|0657
Chloroform|67-66-3|Not Assessed under the IRIS program.||||||
Chloromethyl methyl ether (CMME)|107-30-2|Not Assessed under the IRIS program.||||||
beta-Chloronaphthalene|91-58-7|Not Assessed under the IRIS program.||||||
2-Chlorophenol|95-57-8|Not Assessed under the IRIS program.||||||
p-Chlorophenyl methyl sulfide|123-09-1|Not Assessed under the IRIS program.||||||
p-Chlorophenyl methyl sulfone|98-57-7|Not Assessed under the IRIS program.||||||
p-Chlorophenyl methyl sulfoxide|934-73-6|Not Assessed under the IRIS program.||||||
Chloroprene|126-99-8|Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively|mg /m<sup>3</sup>|2x10<sup>-2</sup>|BMDL (HEC)|2|Medium/High|1021
Chlorothalonil|1897-45-6|Not Assessed under the IRIS program.||||||
o-Chlorotoluene|95-49-8|Not Assessed under the IRIS program.||||||
Chlorpropham|101-21-3|Not Assessed under the IRIS program.||||||
Chlorpyrifos|2921-88-2|Not Assessed under the IRIS program.||||||
Chlorsulfuron|64902-72-3|Not Assessed under the IRIS program.||||||
Chromium(III), insoluble salts|16065-83-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0028
Chromium(VI) (Chromic acid mists and dissolved Cr(VI) aerosols)|18540-29-9|Nasal septum atrophy|mg /m<sup>3</sup>|8x10<sup>-6</sup>|LOAEL (ADJ)|0.000714|Low|0144
Chromium(VI) (Cr(VI) particulates)|18540-29-9|Lactate dehydrogenase in bronchioalveolar lavage fluid||1x10<sup>-4</sup>|BMC<sub>10</sub> (ADJ)|0.034|Medium|0144
Chrysene|218-01-9|Not Assessed under the IRIS program.||||||
Coke oven emissions|8007-45-2|Not Assessed under the IRIS program.||||||
Copper|7440-50-8|Not Assessed under the IRIS program.||||||
Copper cyanide|544-92-3|Not Assessed under the IRIS program.||||||
Creosote|8001-58-9|Not Assessed under the IRIS program.||||||
Crotonaldehyde|123-73-9|Not Assessed under the IRIS program.||||||
Cumene|98-82-8|Increased kidney weights in female rats and adrenal weights in male and female rats|mg /m<sup>3</sup>|4x10<sup>-1</sup>|NOAEL (HEC)|435|Medium|0306
Cyanazine|21725-46-2|Not Assessed under the IRIS program.||||||
Cyanide, free|57-12-5|Not Assessed under the IRIS program.||||||
Cyanogen|460-19-5|Not Assessed under the IRIS program.||||||
Cyanogen bromide|506-68-3|Not Assessed under the IRIS program.||||||
Cyclohexane|110-82-7|Reduced pup weights in the F1 and F2 generations|mg /m<sup>3</sup>|6|BMCL<sub>1sd</sub> (HEC)|1822|Low/Medium|1005
Cyclohexanone|108-94-1|Not Assessed under the IRIS program.||||||
Cyclohexylamine|108-91-8|Not Assessed under the IRIS program.||||||
Cyhalothrin/Karate|68085-85-8|Not Assessed under the IRIS program.||||||
Cypermethrin|52315-07-8|Not Assessed under the IRIS program.||||||
Cyromazine|66215-27-8|Not Assessed under the IRIS program.||||||
Dacthal|1861-32-1|Not Assessed under the IRIS program.||||||
Dalapon, sodium salt|75-99-0|Not Assessed under the IRIS program.||||||
Danitol|39515-41-8|Not Assessed under the IRIS program.||||||
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)|1163-19-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0035
Demeton|8065-48-3|Not Assessed under the IRIS program.||||||
Di (2-ethylhexyl)phthalate (DEHP)|117-81-7|Not Assessed under the IRIS program.||||||
Di(2-ethylhexyl)adipate|103-23-1|Not Assessed under the IRIS program.||||||
2,4-Diaminotoluene|95-80-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0536
Diazomethane|334-88-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0616
Dibenz[a,h]anthracene|53-70-3|Not Assessed under the IRIS program.||||||
Dibenzofuran|132-64-9|Not Assessed under the IRIS program.||||||
1,2-Dibromo-3-chloropropane (DBCP)|96-12-8|Testicular effects|mg /m<sup>3</sup>|2x10<sup>-4</sup>|NOAEL (HEC)|0.17|Medium|0414
1,4-Dibromobenzene|106-37-6|Not Assessed under the IRIS program.||||||
Dibromochloromethane|124-48-1|Not Assessed under the IRIS program.||||||
Dibromodichloromethane|594-18-3|Not Assessed under the IRIS program.||||||
p,p'-Dibromodiphenyl ether|2050-47-7|Not Assessed under the IRIS program.||||||
1,2-Dibromoethane|106-93-4|Nasal inflammation|mg /m<sup>3</sup>|9x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|2.8|Medium|0361
Dibutyl phthalate|84-74-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0038
Dicamba|1918-00-9|Not Assessed under the IRIS program.||||||
Dichloroacetic acid|79-43-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0654
1,3-Dichlorobenzene|541-73-1|Not Assessed under the IRIS program.||||||
1,4-Dichlorobenzene|106-46-7|Increased liver weights in P1 males|mg /m<sup>3</sup>|8x10<sup>-1</sup>|NOAEL (HEC)|75|Medium|0552
1,2-Dichlorobenzene|95-50-1|Not Assessed under the IRIS program.||||||
3,3'-Dichlorobenzidine|91-94-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0504
Dichlorodifluoromethane|75-71-8|Not Assessed under the IRIS program.||||||
p,p'-Dichlorodiphenyl dichloroethane (DDD)|72-54-8|Not Assessed under the IRIS program.||||||
p,p'-Dichlorodiphenyldichloroethylene (DDE)|72-55-9|Not Assessed under the IRIS program.||||||
p,p'-Dichlorodiphenyltrichloroethane (DDT)|50-29-3|Not Assessed under the IRIS program.||||||
1,2-Dichloroethane|107-06-2|Not Assessed under the IRIS program.||||||
1,1-Dichloroethane|75-34-3|Not Assessed under the IRIS program.||||||
trans-1,2-Dichloroethylene|156-60-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0314
cis-1,2-Dichloroethylene|156-59-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0418
1,1-Dichloroethylene (1,1-DCE)|75-35-4|Liver toxicity (fatty change)|mg /m<sup>3</sup>|2x10<sup>-1</sup>|BMCL<sub>10</sub> (HEC)|6.9|Medium|0039
Dichloromethane|75-09-2|Hepatic effects (hepatic vacuolation)|mg /m<sup>3</sup>|6x10<sup>-1</sup>|BMDL<sub>10</sub> (HEC)|17.2|Medium/High|0070
2,4-Dichlorophenol|120-83-2|Not Assessed under the IRIS program.||||||
4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB)|94-82-6|Not Assessed under the IRIS program.||||||
2,4-Dichlorophenoxyacetic acid (2,4-D)|94-75-7|Not Assessed under the IRIS program.||||||
1,2-Dichloropropane|78-87-5|Hyperplasia of the nasal mucosa|mg /m<sup>3</sup>|4x10<sup>-3</sup>|LOAEL (HEC)|1.3|Medium|0601
2,3-Dichloropropanol|616-23-9|Not Assessed under the IRIS program.||||||
1,3-Dichloropropene|542-75-6|Hypertrophy/ hyperplasia of the nasal respiratory epithelium|mg /m<sup>3</sup>|2x10<sup>-2</sup>|BMCL<sub>10</sub> (HEC)|0.72|High|0224
Dichlorvos|62-73-7|Decreased brain cholinesterase activity|mg /m<sup>3</sup>|5x10<sup>-4</sup>|NOAEL (HEC)|0.05|Medium|0151
Dicofol|115-32-2|Not Assessed under the IRIS program.||||||
Dieldrin|60-57-1|Not Assessed under the IRIS program.||||||
Diesel engine exhaust|NA|Pulmonary inflammation and histopathology|mg /m<sup>3</sup>|5x10<sup>-3</sup>|NOAEL (HEC)|0.144|Medium|0642
Diethyl phthalate|84-66-2|Not Assessed under the IRIS program.||||||
Diethyl sulfate|64-67-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0615
Diethyl-p-nitrophenylphosphate|311-45-5|Not Assessed under the IRIS program.||||||
Diethylene glycol dinitrate (DEGDN)|693-21-0|Not Assessed under the IRIS program.||||||
Difenzoquat|43222-48-6|Not Assessed under the IRIS program.||||||
Diflubenzuron|35367-38-5|Not Assessed under the IRIS program.||||||
1,1-Difluoroethane|75-37-6|No adverse effects observed|mg /m<sup>3</sup>|4x10<sup>1</sup>|NOAEL (HEC)|12051|Medium|0665
Diisopropyl methylphosphonate (DIMP)|1445-75-6|Not Assessed under the IRIS program.||||||
Dimethipin|55290-64-7|Not Assessed under the IRIS program.||||||
Dimethoate|60-51-5|Not Assessed under the IRIS program.||||||
Dimethyl phthalate|131-11-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0353
Dimethyl sulfate|77-78-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0365
Dimethyl terephthalate (DMT)|120-61-6|Not Assessed under the IRIS program.||||||
Dimethylamine|124-40-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0228
N-N-Dimethylaniline|121-69-7|Not Assessed under the IRIS program.||||||
3,3-Dimethylbenzidine|119-93-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0538
N,N-Dimethylformamide|68-12-2|Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities|mg /m<sup>3</sup>|3x10<sup>-2</sup>|LOAEL (HEC)|7.9|Medium|0511
3,4-Dimethylphenol|95-65-8|Not Assessed under the IRIS program.||||||
2,6-Dimethylphenol|576-26-1|Not Assessed under the IRIS program.||||||
2,4-Dimethylphenol|105-67-9|Not Assessed under the IRIS program.||||||
4,6-Dinitro-o-cyclohexyl phenol|131-89-5|Not Assessed under the IRIS program.||||||
m-Dinitrobenzene|99-65-0|Not Assessed under the IRIS program.||||||
o-Dinitrobenzene|528-29-0|Not Assessed under the IRIS program.||||||
2,4-Dinitrophenol|51-28-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0152
2,4-Dinitrotoluene|121-14-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0542
2,4-/2,6-Dinitrotoluene mixture|NA|Not Assessed under the IRIS program.||||||
Dinoseb|88-85-7|Not Assessed under the IRIS program.||||||
1,4-Dioxane|123-91-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0326
Diphenamid|957-51-7|Not Assessed under the IRIS program.||||||
Diphenylamine|122-39-4|Not Assessed under the IRIS program.||||||
1,2-Diphenylhydrazine|122-66-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0049
Diquat|85-00-7|Not Assessed under the IRIS program.||||||
Disulfoton|298-04-4|Not Assessed under the IRIS program.||||||
1,4-Dithiane|505-29-3|Not Assessed under the IRIS program.||||||
Diuron|330-54-1|Not Assessed under the IRIS program.||||||
Dodine|2439-10-3|Not Assessed under the IRIS program.||||||
Endosulfan|115-29-7|Not Assessed under the IRIS program.||||||
Endothall|145-73-3|Not Assessed under the IRIS program.||||||
Endrin|72-20-8|Not Assessed under the IRIS program.||||||
Epichlorohydrin|106-89-8|Changes in the nasal turbinates|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|0.36|Medium|0050
1,2-Epoxybutane (EBU)|106-88-7|Degenerative lesions of the nasal cavity|mg /m<sup>3</sup>|2x10<sup>-2</sup>|LOAEL (HEC)|4.8|Medium|0630
Ethephon|16672-87-0|Not Assessed under the IRIS program.||||||
Ethion|563-12-2|Not Assessed under the IRIS program.||||||
2-Ethoxyethanol|110-80-5|Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin|mg /m<sup>3</sup>|2x10<sup>-1</sup>|NOAEL (HEC)|68|Medium|0513
Ethyl acetate|141-78-6|Not Assessed under the IRIS program.||||||
Ethyl carbamate|51-79-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0629
Ethyl chloride|75-00-3|Delayed fetal ossification|mg /m<sup>3</sup>|1x10<sup>1<7sup>|NOAEL (HEC)|4000|Medium|0523
S-Ethyl dipropylthiocarbamate (EPTC)|759-94-4|Not Assessed under the IRIS program.||||||
Ethyl ether|60-29-7|Not Assessed under the IRIS program.||||||
Ethyl p-nitrophenyl phenylphosphorothioate (EPN)|2104-64-5|Not Assessed under the IRIS program.||||||
Ethylbenzene|100-41-4|Developmental toxicity|mg /m<sup>3</sup>|1|NOAEL (HEC)|434|Low|0051
Ethylene diamine|107-15-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0528
Ethylene glycol|107-21-1|Not Assessed under the IRIS program.||||||
Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)|111-76-2|Hemosiderin deposition in the liver|mg /m<sup>3</sup>|1.6|BMCL (HEC)|16|Medium/High|0500
Ethylene thiourea (ETU)|96-45-7|Not Assessed under the IRIS program.||||||
Ethyleneimine|151-56-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0631
Ethylphthalyl ethylglycolate (EPEG)|84-72-0|Not Assessed under the IRIS program.||||||
Express|101200-48-0|Not Assessed under the IRIS program.||||||
Fenamiphos|22224-92-6|Not Assessed under the IRIS program.||||||
Fluometuron|2164-17-2|Not Assessed under the IRIS program.||||||
Fluoranthene|206-44-0|Not Assessed under the IRIS program.||||||
Fluorene|86-73-7|Not Assessed under the IRIS program.||||||
Fluorine (soluble fluoride)|7782-41-4|Not Assessed under the IRIS program.||||||
Fluridone|59756-60-4|Not Assessed under the IRIS program.||||||
Flurprimidol|56425-91-3|Not Assessed under the IRIS program.||||||
Flutolanil|66332-96-5|Not Assessed under the IRIS program.||||||
Fluvalinate|69409-94-5|Not Assessed under the IRIS program.||||||
Folpet|133-07-3|Not Assessed under the IRIS program.||||||
Fomesafen|72178-02-0|Not Assessed under the IRIS program.||||||
Fonofos|944-22-9|Not Assessed under the IRIS program.||||||
Formaldehyde|50-00-0|Not Assessed under the IRIS program.||||||
Formic acid|64-18-6|Not Assessed under the IRIS program.||||||
Fosetyl-al|39148-24-8|Not Assessed under the IRIS program.||||||
Furan|110-00-9|Not Assessed under the IRIS program.||||||
Furfural|98-01-1|Not Assessed under the IRIS program.||||||
Furmecyclox|60568-05-0|Not Assessed under the IRIS program.||||||
Glufosinate-ammonium|77182-82-2|Not Assessed under the IRIS program.||||||
Glycidaldehyde|765-34-4|Not Assessed under the IRIS program.||||||
Glyphosate|1071-83-6|Not Assessed under the IRIS program.||||||
Haloxyfop-methyl|69806-40-2|Not Assessed under the IRIS program.||||||
Harmony|79277-27-3|Not Assessed under the IRIS program.||||||
Heptachlor|76-44-8|Not Assessed under the IRIS program.||||||
Heptachlor epoxide|1024-57-3|Not Assessed under the IRIS program.||||||
n-Heptane|142-82-5|Not Assessed under the IRIS program.||||||
Hexabromobenzene|87-82-1|Not Assessed under the IRIS program.||||||
Hexabromodiphenyl ether|36483-60-0|Not Assessed under the IRIS program.||||||
2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)|68631-49-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1009
Hexachlorobenzene|118-74-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0374
Hexachlorobutadiene|87-68-3|Not Assessed under the IRIS program.||||||
alpha-Hexachlorocyclohexane (alpha-HCH)|319-84-6|Not Assessed under the IRIS program.||||||
beta-Hexachlorocyclohexane (beta-HCH)|319-85-7|Not Assessed under the IRIS program.||||||
delta-Hexachlorocyclohexane (delta-HCH)|319-86-8|Not Assessed under the IRIS program.||||||
epsilon-Hexachlorocyclohexane (epsilon-HC)|6108-10-7|Not Assessed under the IRIS program.||||||
gamma-Hexachlorocyclohexane (gamma-HCH)|58-89-9|Not Assessed under the IRIS program.||||||
technical Hexachlorocyclohexane (t-HCH)|608-73-1|Not Assessed under the IRIS program.||||||
Hexachlorocyclopentadiene (HCCPD)|77-47-4|Suppurative inflammation of the nose|mg /m<sup>3</sup>|2x10<sup>-4</sup>|NOAEL (HEC)|0.024|Medium|0059
Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD|57653-85-7|Not Assessed under the IRIS program.||||||
Hexachloroethane|67-72-1|Neurotoxicity (tremors and ruffled pelt)|mg /m<sup>3</sup>|3x10<sup>-2</sup>|NOAEL (HEC)|83|Low|0167
Hexachlorophene|70-30-4|Not Assessed under the IRIS program.||||||
Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)|121-82-4|Not Assessed under the IRIS program.||||||
1,6-Hexamethylene diisocyanate|822-06-0|Degeneration of olfactory epithelium|mg /m<sup>3</sup|1x10<sup>-5</sup>|NOAEL (HEC)|0.001|Medium|0638
n-Hexane|110-54-3|Peripheral neuropathy (decreased MCV at 12 weeks)|mg /m<sup>3</sup>|7x10<sup>-1</sup>|BMCL (HEC)|215|Medium|0486
2-Hexanone|591-78-6|Motor conduction velocity of the sciatic-tibial nerve|mg /m<sup>3</sup>|3x10<sup>-2</sup>|BMCL<sub>05</sub> (HEC)|90|Low|1019
Hexazinone|51235-04-2|Not Assessed under the IRIS program.||||||
Hydrazine/Hydrazine sulfate|302-01-2|Not Assessed under the IRIS program.||||||
Hydrogen Cyanide and Cyanide Salts|Various|Thyroid enlargement and altered iodide uptake|mg /m<sup>3</sup>|0.0008|LOAEL (ADJ)|2.5|Low/Medium|0060
Hydrogen chloride|7647-01-0|Hyperplasia of nasal mucosa larynx and trachea|mg /m<sup>3</sup>|2x10<sup>-2</sup>|LOAEL (HEC)|6.1|Low|0396
Hydrogen sulfide|7783-06-4|Nasal lesions of the olfactory mucosa|mg /m<sup>3</sup>|2x10<sup>-3</sup>|NOAEL (HEC)|0.64|Medium/High|0061
Hydroquinone|123-31-9|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Imazalil|35554-44-0|Not Assessed under the IRIS program.||||||
Imazaquin|81335-37-7|Not Assessed under the IRIS program.||||||
Indeno[1,2,3-cd]pyrene|193-39-5|Not Assessed under the IRIS program.||||||
Iprodione|36734-19-7|Not Assessed under the IRIS program.||||||
Isobutyl alcohol|78-83-1|Not Assessed under the IRIS program.||||||
Isophorone|78-59-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Isopropalin|33820-53-0|Not Assessed under the IRIS program.||||||
Isopropyl methyl phosphonic acid (IMPA)|1832-54-8|Not Assessed under the IRIS program.||||||
Isoxaben|82558-50-7|Not Assessed under the IRIS program.||||||
Lactofen|77501-63-4|Not Assessed under the IRIS program.||||||
Lead and compounds (inorganic)|7439-92-1|Not Assessed under the IRIS program.||||||
d-Limonene|5989-27-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Linuron|330-55-2|Not Assessed under the IRIS program.||||||
Londax|83055-99-6|Not Assessed under the IRIS program.||||||
Malathion|121-75-5|Not Assessed under the IRIS program.||||||
Maleic anhydride|108-31-6|Not Assessed under the IRIS program.||||||
Maleic hydrazide|123-33-1|Not Assessed under the IRIS program.||||||
Maneb|12427-38-2|Not Assessed under the IRIS program.||||||
Manganese|7439-96-5|Impairment of neurobehavioral function (other effect: Impairment of neurobehavioral function)|mg /m<sup>3</sup>|5x10<sup>-5</sup>|LOAEL (HEC)|0.05|Medium|0373
Mepiquat chloride|24307-26-4|Not Assessed under the IRIS program.||||||
Mercuric chloride (HgCl2)|7487-94-7|Not Assessed under the IRIS program.||||||
Mercury, elemental|7439-97-6|Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction|mg /m<sup>3</sup>|3x10<sup>-4</sup>|LOAEL (ADJ)|0.009|Medium|0370
Merphos|150-50-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Merphos oxide|78-48-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Metalaxyl|57837-19-1|Not Assessed under the IRIS program.||||||
Methacrylonitrile|126-98-7|Not Assessed under the IRIS program.||||||
Methamidophos|10265-92-6|Not Assessed under the IRIS program.||||||
Methanol|67-56-1|Not Assessed under the IRIS program.||||||
Methidathion|950-37-8|Not Assessed under the IRIS program.||||||
Methomyl|16752-77-5|Not Assessed under the IRIS program.||||||
Methoxychlor|72-43-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
2-Methoxyethanol|109-86-4|Testicular effects|mg /m<sup>3</sup>|2x10<sup>-2</sup>|NOAEL (HEC)|17|Medium|0525
Methyl acrylate|96-33-3|Not Assessed under the IRIS program.||||||
Methyl chloride|74-87-3|Cerebellar lesions|mg /m<sup>3</sup>|9x10<sup>-2</sup>|NOAEL (HEC)|94.6|Medium|1003
Methyl chlorocarbonate|79-22-1|Not Assessed under the IRIS program.||||||
Methyl ethyl ketone (MEK)|78-93-3|Developmental toxicity (skeletal variations)|mg /m<sup>3</sup>|5|LEC (HEC)|1517|Medium|0071
Methyl iodide|74-88-4|Not Assessed under the IRIS program.||||||
Methyl isobutyl ketone (MIBK)|108-10-1|Reduced fetal body weight, skeletal variations, and increased fetal death in mice, and skeletal variations in rats|mg /m<sup>3</sup>|3|NOAEL (HEC)|1026|Low/Medium|0173
Methyl isocyanate|624-83-9|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Methyl methacrylate|80-62-6|Degeneration/ atrophy of olfactory epithelium (male rats)|mg /m<sup>3</sup>|7x10<sup>-1</sup>|BMC<sub>10</sub> (HEC)|7.2|Medium/High|1000
Methyl parathion|298-00-0|Not Assessed under the IRIS program.||||||
Methyl tert-butyl ether (MTBE)|1634-04-4|Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females)|mg /m<sup>3</sup>|3|NOAEL (HEC)|259|Medium|0545
4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB)|94-81-5|Not Assessed under the IRIS program.||||||
2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP)|93-65-2|Not Assessed under the IRIS program.||||||
2-Methyl-4-chlorophenoxyacetic acid (MCPA)|94-74-6|Not Assessed under the IRIS program.||||||
Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)|101-68-8|Hyperplasia of olfactory epithelium|mg /m<sup>3</sup>|6x10<sup>-4</sup>|BMC<sup>10</sup> (HEC)|0.06|Medium|0529
4,4'-Methylene bis(N,N'-dimethyl)aniline|101-61-1|Not Assessed under the IRIS program.||||||
Methylmercury (MeHg)|22967-92-6|Not Assessed under the IRIS program.||||||
2-Methylnaphthalene|91-57-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
4-Methylphenol|106-44-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
3-Methylphenol|108-39-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
2-Methylphenol|95-48-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Metolachlor|51218-45-2|Not Assessed under the IRIS program.||||||
Metribuzin|21087-64-9|Not Assessed under the IRIS program.||||||
Mirex|2385-85-5|Not Assessed under the IRIS program.||||||
Molinate|2212-67-1|Not Assessed under the IRIS program.||||||
Molybdenum|7439-98-7|Not Assessed under the IRIS program.||||||
Monochloramine|10599-90-3|Not Assessed under the IRIS program.||||||
Naled|300-76-5|Not Assessed under the IRIS program.||||||
Naphthalene|91-20-3|Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively|mg /m<sup>3</sup>|3x10<sup>-3</sup>|LOAEL (HEC)|9.3|Medium|0436
Napropamide|15299-99-7|Not Assessed under the IRIS program.||||||
Nickel carbonyl|13463-39-3|Not Assessed under the IRIS program.||||||
Nickel refinery dust|NA|Not Assessed under the IRIS program.||||||
Nickel subsulfide|12035-72-2|Not Assessed under the IRIS program.||||||
Nickel, soluble salts|NA|Not Assessed under the IRIS program.||||||
Nitrapyrin|1929-82-4|Not Assessed under the IRIS program.||||||
Nitrate|14797-55-8|Not Assessed under the IRIS program.||||||
Nitric oxide|10102-43-9|Not Assessed under the IRIS program.||||||
Nitrite|14797-65-0|Not Assessed under the IRIS program.||||||
Nitrobenzene|98-95-3|Bronchiolization of the alveoli and olfactory degeneration|mg /m<sup>3</sup>|9x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|0.26|Medium|0079
Nitrogen dioxide|10102-44-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Nitroguanidine|556-88-7|Not Assessed under the IRIS program.||||||
p-Nitrophenol|100-02-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
2-Nitropropane|79-46-9|Liver focal vacuolization and nodules|mg /m<sup>3</sup>|2x10<sup>-2</sup>|LOAEL (HEC)|16|Low|0519
N-Nitroso-N-methylethylamine|10595-95-6|Not Assessed under the IRIS program.||||||
N-Nitroso-di-n-butylamine|924-16-3|Not Assessed under the IRIS program.||||||
N-Nitrosodi-N-propylamine|621-64-7|Not Assessed under the IRIS program.||||||
N-Nitrosodiethanolamine|1116-54-7|Not Assessed under the IRIS program.||||||
N-Nitrosodiethylamine|55-18-5|Not Assessed under the IRIS program.||||||
N-Nitrosodimethylamine|62-75-9|Not Assessed under the IRIS program.||||||
N-Nitrosodiphenylamine|86-30-6|Not Assessed under the IRIS program.||||||
N-Nitrosopyrrolidine|930-55-2|Not Assessed under the IRIS program.||||||
Nonabromodiphenyl ether|63936-56-1|Not Assessed under the IRIS program.||||||
Norflurazon|27314-13-2|Not Assessed under the IRIS program.||||||
NuStar|85509-19-9|Not Assessed under the IRIS program.||||||
Octabromodiphenyl ether|32536-52-0|Not Assessed under the IRIS program.||||||
Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX)|2691-41-0|Not Assessed under the IRIS program.||||||
Oryzalin|19044-88-3|Not Assessed under the IRIS program.||||||
Oxadiazon|19666-30-9|Not Assessed under the IRIS program.||||||
Oxamyl|23135-22-0|Not Assessed under the IRIS program.||||||
Oxyfluorfen|42874-03-3|Not Assessed under the IRIS program.||||||
Paclobutrazol|76738-62-0|Not Assessed under the IRIS program.||||||
Paraquat|1910-42-5|Not Assessed under the IRIS program.||||||
Parathion|56-38-2|Not Assessed under the IRIS program.||||||
Pendimethalin|40487-42-1|Not Assessed under the IRIS program.||||||
Pentabromodiphenyl ether|32534-81-9|Not Assessed under the IRIS program.||||||
2,2',4,4',5-Pentabromodiphenyl ether (BDE-99)|60348-60-9|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Pentachlorobenzene|608-93-5|Not Assessed under the IRIS program.||||||
Pentachlorocyclopentadiene|25329-35-5|Not Assessed under the IRIS program.||||||
Pentachloronitrobenzene (PCNB)|82-68-8|Not Assessed under the IRIS program.||||||
Pentachlorophenol|87-86-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Pentafluoroethane|354-33-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Perchlorate (ClO4) and Perchlorate Salts|7790-98-9|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Permethrin|52645-53-1|Not Assessed under the IRIS program.||||||
Phenanthrene|85-01-8|Not Assessed under the IRIS program.||||||
Phenmedipham|13684-63-4|Not Assessed under the IRIS program.||||||
Phenol|108-95-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
m-Phenylenediamine|108-45-2|Not Assessed under the IRIS program.||||||
Phenylmercuric acetate|62-38-4|Not Assessed under the IRIS program.||||||
Phosalone|2310-17-0|Not Assessed under the IRIS program.||||||
Phosgene|75-44-5|Collagen staining indicative of fibrosis|mg /m<sup>3</sup>|3x10<sup>-4</sup>|BMDL<sub>10</sub> (HEC)|0.03|Medium|0487
Phosmet|732-11-6|Not Assessed under the IRIS program.||||||
Phosphine|7803-51-2|Decreased body weight|mg /m<sup>3</sup>|3x10<sup>-4</sup>|NOAEL (HEC)|0.25|Low|0090
Phosphoric acid|7664-38-2|Bronchiolar fibrosis|mg /m<sup>3</sup>|1x10<sup>-2</sup>|BMC<sub>10</sub> (HEC)|3.4|Medium|0697
Phthalic anhydride|85-44-9|Not Assessed under the IRIS program.||||||
Picloram|1918-02-1|Not Assessed under the IRIS program.||||||
Pirimiphos-methyl|29232-93-7|Not Assessed under the IRIS program.||||||
Polychlorinated biphenyls (PCBs)|1336-36-3|Not Assessed under the IRIS program.||||||
Potassium cyanide|151-50-8|Not Assessed under the IRIS program.||||||
Potassium silver cyanide|506-61-6|Not Assessed under the IRIS program.||||||
Prochloraz|67747-09-5|Not Assessed under the IRIS program.||||||
Prometon|1610-18-0|Not Assessed under the IRIS program.||||||
Prometryn|7287-19-6|Not Assessed under the IRIS program.||||||
Pronamide|23950-58-5|Not Assessed under the IRIS program.||||||
Propachlor|1918-16-7|Not Assessed under the IRIS program.||||||
Propanil|709-98-8|Not Assessed under the IRIS program.||||||
Propargite|2312-35-8|Not Assessed under the IRIS program.||||||
Propargyl alcohol|107-19-7|Not Assessed under the IRIS program.||||||
Propazine|139-40-2|Not Assessed under the IRIS program.||||||
Propham|122-42-9|Not Assessed under the IRIS program.||||||
Propiconazole|60207-90-1|Not Assessed under the IRIS program.||||||
beta-Propiolactone|57-57-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Propionaldehyde|123-38-6|Atrophy of olfactory epithelium|mg /m<sup>3</sup>|8x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|8|Low/Medium|1011
Propylene glycol|57-55-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Propylene glycol monoethyl ether|52125-53-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Propylene glycol monomethyl ether (PGME)|107-98-2|Mild reversible sedation|mg /m<sup>3</sup>|2|NOAEL (HEC)|658|Medium|0404
Propylene oxide|75-56-9|Nest-like infolds of the nasal respiratory epithelium|mg /m<sup>3</sup>|3x10<sup>-2</sup>|LOAEL (HEC)|2.9|Medium|0403
Propyleneimine|75-55-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Pursuit|81335-77-5|Not Assessed under the IRIS program.||||||
Pydrin|51630-58-1|Not Assessed under the IRIS program.||||||
Pyrene|129-00-0|Not Assessed under the IRIS program.||||||
Pyridine|110-86-1|Not Assessed under the IRIS program.||||||
Quinalphos|13593-03-8|Not Assessed under the IRIS program.||||||
Quinoline|91-22-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Quinone|106-51-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Radium 226,228|7440-14-4|Not Assessed under the IRIS program.||||||
Radon 222|14859-67-7|Not Assessed under the IRIS program.||||||
Refractory ceramic fibers|NA|Not Assessed under the IRIS program.||||||
Resmethrin|10453-86-8|Not Assessed under the IRIS program.||||||
Rotenone|83-79-4|Not Assessed under the IRIS program.||||||
Savey|78587-05-0|Not Assessed under the IRIS program.||||||
Selenious acid|7783-00-8|Not Assessed under the IRIS program.||||||
Selenium and Compounds|7782-49-2|Not Assessed under the IRIS program.||||||
Selenium sulfide|7446-34-6|Not Assessed under the IRIS program.||||||
Selenourea|630-10-4|Not Assessed under the IRIS program.||||||
Sethoxydim|74051-80-2|Not Assessed under the IRIS program.||||||
Silver|7440-22-4|Not Assessed under the IRIS program.||||||
Silver cyanide|506-64-9|Not Assessed under the IRIS program.||||||
Simazine|122-34-9|Not Assessed under the IRIS program.||||||
Sodium azide|26628-22-8|Not Assessed under the IRIS program.||||||
Sodium cyanide|143-33-9|Not Assessed under the IRIS program.||||||
Sodium diethyldithiocarbamate|148-18-5|Not Assessed under the IRIS program.||||||
Sodium fluoroacetate|62-74-8|Not Assessed under the IRIS program.||||||
Strontium|7440-24-6|Not Assessed under the IRIS program.||||||
Strychnine|57-24-9|Not Assessed under the IRIS program.||||||
Styrene|100-42-5|CNS effects|mg /m<sup>3</sup>|1|NOAEL (HEC)|34|Medium|0104
Systhane|88671-89-0|Not Assessed under the IRIS program.||||||
Tebuthiuron|34014-18-1|Not Assessed under the IRIS program.||||||
Terbacil|5902-51-2|Not Assessed under the IRIS program.||||||
Terbutryn|886-50-0|Not Assessed under the IRIS program.||||||
Tetrabromodiphenyl ether|40088-47-9|Not Assessed under the IRIS program.||||||
2,2',4,4'-Tetrabromodiphenyl ether (BDE-47)|5436-43-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
1,2,4,5-Tetrachlorobenzene|95-94-3|Not Assessed under the IRIS program.||||||
Tetrachlorocyclopentadiene|695-77-2|Not Assessed under the IRIS program.||||||
2,3,7,8-Tetrachlorodibenzo-p-dioxin|1746-01-6|Not Assessed under the IRIS program.||||||
1,1,1,2-Tetrachloroethane|630-20-6|Not Assessed under the IRIS program.||||||
1,1,2,2-Tetrachloroethane|79-34-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Tetrachloroethylene|127-18-4|Not Assessed under the IRIS program.||||||
2,3,4,6-Tetrachlorophenol|58-90-2|Not Assessed under the IRIS program.||||||
Tetrachlorovinphos|961-11-5|Not Assessed under the IRIS program.||||||
Tetraethyl lead|78-00-2|Not Assessed under the IRIS program.||||||
Tetraethyldithiopyrophosphate|3689-24-5|Not Assessed under the IRIS program.||||||
1,1,1,2-Tetrafluoroethane|811-97-2|Leydig cell hyperplasia|mg /m<sup>3</sup>|8x10<sup>1</sup>|BMC<sub>10</sub> (HEC)|8200|Medium|0656
Thallium (I), soluble salts|Various|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Thallium acetate|563-68-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Thallium carbonate|6533-73-9|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Thallium chloride|7791-12-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Thallium nitrate|10102-45-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Thallium oxide|1314-32-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Thallium selenite|12039-52-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Thallium(I) sulfate|7446-18-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Thiobencarb|28249-77-6|Not Assessed under the IRIS program.||||||
Thiophanate-methyl|23564-05-8|Not Assessed under the IRIS program.||||||
Thiram|137-26-8|Not Assessed under the IRIS program.||||||
Toluene|108-88-3|Neurological effects in occupationally-exposed workers (other effect:)|mg /m<sup>3</sup>|5|NOAEL (ADJ)|46|High|0118
2,4-/2,6-Toluene diisocyanate mixture (TDI)|26471-62-5|Chronic lung-function decline|mg /m<sup>3</sup>|7x10<sup>-5</sup>|NOAEL (HEC)|0.002|Medium|0503
Toxaphene|8001-35-2|Not Assessed under the IRIS program.||||||
Tralomethrin|66841-25-6|Not Assessed under the IRIS program.||||||
Triallate|2303-17-5|Not Assessed under the IRIS program.||||||
Triasulfuron|82097-50-5|Not Assessed under the IRIS program.||||||
1,2,4-Tribromobenzene|615-54-3|Not Assessed under the IRIS program.||||||
Tribromochloromethane|594-15-0|Not Assessed under the IRIS program.||||||
Tribromodiphenyl ether|49690-94-0|Not Assessed under the IRIS program.||||||
Tributyltin oxide (TBTO)|56-35-9|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113)|76-13-1|Not Assessed under the IRIS program.||||||
Trichloroacetic acid|76-03-9|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
1,2,4-Trichlorobenzene|120-82-1|Not Assessed under the IRIS program.||||||
Trichlorocyclopentadiene|77323-84-3|Not Assessed under the IRIS program.||||||
1,1,2-Trichloroethane|79-00-5|Not Assessed under the IRIS program.||||||
1,1,1-Trichloroethane|71-55-6|Liver histopathologic changes|mg /m<sup>3</sup>|5|NOEL (HEC)|1553|Medium|0197
Trichloroethylene|79-01-6|Decreased thymus weight in female B6C3F1 mice (immunotoxicity)|mg /m<sup>3</sup>|0.002|LOAEL (HEC<sub>99</sub>)|0.19|High|0199
Trichloroethylene|79-01-6|Increased fetal cardiac malformations in Sprague-Dawley rats (heart malformations)|mg /m<sup>3</sup>|0.002|BMDL<sub>01</sub> (HEC<sub>99</sub>)|0.021|High|0199
Trichlorofluoromethane|75-69-4|Not Assessed under the IRIS program.||||||
2,4,5-Trichlorophenol|95-95-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
2,4,6-Trichlorophenol|88-06-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP)|93-72-1|Not Assessed under the IRIS program.||||||
2,4,5-Trichlorophenoxyacetic acid (2,4,5-T)|93-76-5|Not Assessed under the IRIS program.||||||
1,1,2-Trichloropropane|598-77-6|Not Assessed under the IRIS program.||||||
1,2,3-Trichloropropane|96-18-4|peribronchial lymphoid hyperplasia in male rats|mg /m<sup>3</sup>|0.0003|BMCL (HEC)|0.90|Low|0200
Tricresol|1319-77-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Tridiphane|58138-08-2|Not Assessed under the IRIS program.||||||
Triethylamine|121-44-8|No observed adverse effects (other effect: Inflammation of the nasal passage)|mg /m<sup>3</sup>|7x10<sup>-3</sup>|NOAEL (HEC)|19.5|Low|0520
Triethylene glycol monobutyl ether|143-22-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Triethylene glycol monoethyl ether|112-50-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Trifluralin|1582-09-8|Not Assessed under the IRIS program.||||||
2,2,4-Trimethylpentane|540-84-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
1,3,5-Trinitrobenzene|99-35-4|Not Assessed under the IRIS program.||||||
2,4,6-Trinitrotoluene (TNT)|118-96-7|Not Assessed under the IRIS program.||||||
Uranium, natural|7440-61-1|Not Assessed under the IRIS program.||||||
Uranium, soluble salts|NA|Not Assessed under the IRIS program.||||||
Urea|57-13-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
Vanadium pentoxide|1314-62-1|Not Assessed under the IRIS program.||||||
Vernam|1929-77-7|Not Assessed under the IRIS program.||||||
Vinclozolin|50471-44-8|Not Assessed under the IRIS program.||||||
Vinyl acetate|108-05-4|Nasal epithelial lesions|mg /m<sup>3</sup>|2x10<sup>-1</sup>|NOAEL (HEC)|5|High|0512
Vinyl bromide|593-60-2|Hypertrophy, basophilic and eosinophilic foci, in the liver|mg /m<sup>3</sup>|3x10<sup>-3</sup>|LOAEL (HEC)|7.7|Low|0671
Vinyl chloride|75-01-4|Liver cell polymorphism|mg /m<sup>3</sup>|1x10<sup>-1</sup>|NOAEL (HEC)|2.5|Medium|1001
Warfarin|81-81-2|Not Assessed under the IRIS program.||||||
White phosphorus|7723-14-0|Not Assessed under the IRIS program.||||||
Xylenes|1330-20-7|Impaired motor coordination (decreased rotarod performance)|mg /m<sup>3</sup>|0.1|NOAEL (HEC)|39|Medium|0270
Zinc and Compounds|7440-66-6|Not Assessed under the IRIS program.||||||
Zinc cyanide|557-21-1|Not Assessed under the IRIS program.||||||
Zinc phosphide|1314-84-7|Not Assessed under the IRIS program.||||||
Zineb|12122-67-7|Not Assessed under the IRIS program.||||||
</t2b>
 
===Inhalation unit risks===


<t2b index = "Substance,Observation type" locations = "CASRN,Precursor Effect/ Tumor Type,Extrapolation Method,Unit,Inhalation unit risks,Study Route,IRIS identifier" unit = "per µg /m<sup>3</sup>">
* [[IRIS/Oral RfDs]]
Acenaphthene|83-32-9|Not Assessed under the IRIS program.|||||
* [[IRIS/Inhalation RfCs]]
Acenaphthylene|208-96-8|Not Assessed under the IRIS program.|||||
* [[IRIS/Weight-of-Evidence Characterizations]]
Acephate|30560-19-1|Not Assessed under the IRIS program.|||||
* [[IRIS/Inhalation unit risks]]
Acetaldehyde|75-07-0|Nasal squamous cell carcinoma or adenocarcinoma|Linearized multistage-variable exposure input form (extra risk) |per µg/m<sup>3</sup>|2.2x10<sup>-6</sup>|Inhalation|
* [[Template:IRIS links]]
Acetochlor|34256-82-1|Not Assessed under the IRIS program.|||||
Acetone|67-64-1|Not Assessed under the IRIS program.|||||
Acetonitrile|75-05-8|Not Assessed under the IRIS program.|||||
Acetophenone|98-86-2|Not Assessed under the IRIS program.|||||
Acetyl chloride|75-36-5|Not Assessed under the IRIS program.|||||
Acifluorfen, sodium|62476-59-9|Not Assessed under the IRIS program.|||||
Acrolein|107-02-8|Not Assessed under the IRIS program.|||||
Acrylamide|79-06-1|thyroid tumors and tunica vaginalis mesotheliomas|Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.|per µg /m<sup>3</sup>|1x10<sup>-4</sup>|Oral, drinking water|
Acrylic acid|79-10-7|Not Assessed under the IRIS program.|||||
Acrylonitrile|107-13-1|Respiratory cancer|Average relative risk|per µg /m<sup>3</sup>|6.8x10<sup>-5</sup>|Inhalation|
Adiponitrile|111-69-3|Not Assessed under the IRIS program.|||||
Alachlor|15972-60-8|Not Assessed under the IRIS program.|||||
Alar|1596-84-5|Not Assessed under the IRIS program.|||||
Aldicarb|116-06-3|Not Assessed under the IRIS program.|||||
Aldicarb sulfone|1646-88-4|Not Assessed under the IRIS program.|||||
Aldrin|309-00-2|Liver carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|4.9x10<sup>-3</sup>|Oral, Diet|
Ally|74223-64-6|Not Assessed under the IRIS program.|||||
Allyl alcohol|107-18-6|Not Assessed under the IRIS program.|||||
Allyl chloride|107-05-1|Not Assessed under the IRIS program.|||||
Aluminum phosphide|20859-73-8|Not Assessed under the IRIS program.|||||
Amdro|67485-29-4|Not Assessed under the IRIS program.|||||
Ametryn|834-12-8|Not Assessed under the IRIS program.|||||
4-Aminopyridine|504-24-5|Not Assessed under the IRIS program.|||||
Amitraz|33089-61-1|Not Assessed under the IRIS program.|||||
Ammonia|7664-41-7|Not Assessed under the IRIS program.|||||
Ammonium acetate|631-61-8|Not Assessed under the IRIS program.|||||
Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program.|||||
Ammonium sulfamate|7773-06-0|Not Assessed under the IRIS program.|||||
Aniline|62-53-3|Not Assessed under the IRIS program.|||||
ortho-Anisidine|90-04-0|Not Assessed under the IRIS program.|||||
Anthracene|120-12-7|Not Assessed under the IRIS program.|||||
Antimony|7440-36-0|Not Assessed under the IRIS program.|||||
Antimony trioxide|1309-64-4|Not Assessed under the IRIS program.|||||
Apollo|74115-24-5|Not Assessed under the IRIS program.|||||
Aramite|140-57-8|Neoplastic liver nodules and carcinomas|Linearized multistage procedure, extra risk|per µg/m<sup>3</sup>|7.1x10<sup>-6</sup>|Oral, Diet|
Aroclor 1016|12674-11-2|Not Assessed under the IRIS program.|||||
Aroclor 1248|12672-29-6|Not Assessed under the IRIS program.|||||
Aroclor 1254|11097-69-1|Not Assessed under the IRIS program.|||||
Arsenic, inorganic|7440-38-2|Lung cancer|Absolute-risk linear model|per µg/m<sup>3</sup>|4.3x10<sup>-3</sup>|Inhalation, Occupational exposure|
Arsine|7784-42-1|Not Assessed under the IRIS program.|||||
Asbestos|1332-21-4|Lung cancer and mesothelioma|Additive risk of lung cancer and mesothelioma, using relative risk model for lung cancer and absolute risk model for mesothelioma|per f/mL|2.3x10<sup>-1</sup>|Inhalation, Occupational exposure|
Assure|76578-14-8|Not Assessed under the IRIS program.|||||
Asulam|3337-71-1|Not Assessed under the IRIS program.|||||
Atrazine|1912-24-9|Not Assessed under the IRIS program.|||||
Avermectin B1|65195-55-3|Not Assessed under the IRIS program.|||||
Azobenzene|103-33-3|Abdominal cavity sarcomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.1x10<sup>-5</sup>|Oral, Diet|
Barium and Compounds|7440-39-3|Not Assessed under the IRIS program.|||||
Barium cyanide|542-62-1|Not Assessed under the IRIS program.|||||
Baygon|114-26-1|Not Assessed under the IRIS program.|||||
Bayleton|43121-43-3|Not Assessed under the IRIS program.|||||
Baythroid|68359-37-5|Not Assessed under the IRIS program.|||||
Benefin|1861-40-1|Not Assessed under the IRIS program.|||||
Benomyl|17804-35-2|Not Assessed under the IRIS program.|||||
Bentazon (Basagran)|25057-89-0|Not Assessed under the IRIS program.|||||
Benz[a]anthracene|56-55-3|Not Assessed under the IRIS program.|||||
Benzaldehyde|100-52-7|Not Assessed under the IRIS program.|||||
Benzene|71-43-2|Leukemia|Low-dose linearity utilizing maximum likelihood estimates|per µg /m<sup>3</sup>|2.2x10<sup>-6</sup>|Inhalation|
Benzene|71-43-2|Leukemia|Low-dose linearity utilizing maximum likelihood estimates|per µg /m<sup>3</sup>|7.8x10<sup>-6</sup>|Inhalation|
Benzidine|92-87-5|Bladder tumors|One-hit with time factor, extra risk|per µg /m<sup>3</sup>|6.7x10<sup>-2</sup>|Inhalation, Occupational exposure|
Benzo[a]pyrene (BaP)|50-32-8|Not Assessed under the IRIS program.|||||
Benzo[b]fluoranthene|205-99-2|Not Assessed under the IRIS program.|||||
Benzo[g,h,i]perylene|191-24-2|Not Assessed under the IRIS program.|||||
Benzo[k]fluoranthene|207-08-9|Not Assessed under the IRIS program.|||||
Benzoic acid|65-85-0|Not Assessed under the IRIS program.|||||
Benzotrichloride|98-07-7|Not Assessed under the IRIS program.|||||
Benzyl chloride|100-44-7|Not Assessed under the IRIS program.|||||
Beryllium and compounds|7440-41-7|Lung cancer|Relative risk|per µg /m<sup>3</sup>|2.4x10<sup>-3</sup>|Inhalation, Occupational exposure|
Bidrin|141-66-2|Not Assessed under the IRIS program.|||||
Biphenthrin|82657-04-3|Not Assessed under the IRIS program.|||||
1,1-Biphenyl|92-52-4|Not Assessed under the IRIS program.|||||
Bis(2-chloro-1-methylethyl) ether|108-60-1|Not Assessed under the IRIS program.|||||
Bis(2-chloroethoxy)methane|111-91-1|Not Assessed under the IRIS program.|||||
Bis(chloroethyl)ether (BCEE)|111-44-4|Hepatomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.3x10<sup>-4</sup>|Oral, Gavage followed by diet|
Bis(chloromethyl)ether (BCME)|542-88-1|Respiratory tract tumors|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|6.2x10<sup>-2</sup>|Inhalation|
Bisphenol A.|80-05-7|Not Assessed under the IRIS program.|||||
Boron and Compounds|7440-42-8|Not Assessed under the IRIS program.|||||
Bromate|15541-45-4|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Brominated dibenzofurans|NA|Not Assessed under the IRIS program.|||||
Bromobenzene|108-86-1|Not Assessed under the IRIS program.|||||
Bromochloromethane|74-97-5|Not Assessed under the IRIS program.|||||
Bromodichloromethane|75-27-4|Not Assessed under the IRIS program.|||||
p-Bromodiphenyl ether|101-55-3|Not Assessed under the IRIS program.|||||
Bromoform|75-25-2|Neoplastic lesions in the large intestine|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.1x10<sup>-6</sup>|Oral, Gavage in corn oil|
Bromomethane|74-83-9|Not Assessed under the IRIS program.|||||
Bromotrichloromethane|75-62-7|Not Assessed under the IRIS program.|||||
Bromoxynil|1689-84-5|Not Assessed under the IRIS program.|||||
Bromoxynil octanoate|1689-99-2|Not Assessed under the IRIS program.|||||
1,3-Butadiene|106-99-0|Leukemia|Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied.|per µg /m<sup>3</sup>|3x10<sup>-5</sup>|Inhalation|
n-Butanol|71-36-3|Not Assessed under the IRIS program.|||||
Butyl benzyl phthalate|85-68-7|Not Assessed under the IRIS program.|||||
Butylate|2008-41-5|Not Assessed under the IRIS program.|||||
t-Butylchloride|507-20-0|Not Assessed under the IRIS program.|||||
Butylphthalyl butylglycolate (BPBG)|85-70-1|Not Assessed under the IRIS program.|||||
Cacodylic acid|75-60-5|Not Assessed under the IRIS program.|||||
Cadmium|7440-43-9|Lung, trachea, bronchus cancer deaths|Two stage; only first affected by exposure; extra risk|per µg /m<sup>3</sup>|1.8x10<sup>-3</sup>|Inhalation, Exposure in the workplace|
Calcium cyanide|592-01-8|Not Assessed under the IRIS program.|||||
Caprolactam|105-60-2|Not Assessed under the IRIS program.|||||
Captafol|2425-06-1|Not Assessed under the IRIS program.|||||
Captan|133-06-2|Not Assessed under the IRIS program.|||||
Carbary|l63-25-2|Not Assessed under the IRIS program.|||||
Carbofuran1|563-66-2|Not Assessed under the IRIS program.|||||
Carbon disulfide|75-15-0|Not Assessed under the IRIS program.|||||
Carbon tetrachloride|56-23-5|Pheochromocytoma|Log-probit model with linear extrapolation from the POD (LEC10).|per µg /m<sup>3</sup>|6x10<sup>-6</sup>|Inhalation|
Carbonyl sulfide|463-58-1|Not Assessed under the IRIS program.|||||
Carbosulfan|55285-14-8|Not Assessed under the IRIS program.|||||
Carboxin|5234-68-4|Not Assessed under the IRIS program.|||||
Cerium Oxide and Cerium Compounds|1306-38-3|Not Assessed under the IRIS program.|||||
Chloral hydrate|302-17-0|Not Assessed under the IRIS program.|||||
Chloramben|133-90-4|Not Assessed under the IRIS program.|||||
Chlordane (Technical)|12789-03-6|Hepatocellular carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1x10<sup>-4<7sup>|Oral, Diet|
Chlordecone (Kepone)|143-50-0|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Chlorimuron-ethyl|90982-32-4|Not Assessed under the IRIS program.|||||
Chlorine|7782-50-5|Not Assessed under the IRIS program.|||||
Chlorine cyanide|506-77-4|Not Assessed under the IRIS program.|||||
Chlorine dioxide|10049-04-4|Not Assessed under the IRIS program.|||||
Chlorite (sodium salt)|7758-19-2|Not Assessed under the IRIS program.|||||
1-Chloro-1,1-difluoroethane|75-68-3|Not Assessed under the IRIS program.|||||
2-Chloroacetophenone|532-27-4|Not Assessed under the IRIS program.|||||
p-Chloroaniline|106-47-8|Not Assessed under the IRIS program.|||||
Chlorobenzene|108-90-7|Not Assessed under the IRIS program.|||||
Chlorobenzilate|510-15-6|Not Assessed under the IRIS program.|||||
1-Chlorobutane|109-69-3|Not Assessed under the IRIS program.|||||
2-Chlorobutane|78-86-4|Not Assessed under the IRIS program.|||||
Chlorocyclopentadiene|41851-50-7|Not Assessed under the IRIS program.|||||
Chlorodifluoromethane|75-45-6|Not Assessed under the IRIS program.|||||
Chloroform|67-66-3|Hepatocellular carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|2.3x10<sup>-5</sup>|Oral, Gavage|
Chloromethyl methyl ether (CMME)|107-30-2|Not Assessed under the IRIS program.|||||
beta-Chloronaphthalene|91-58-7|Not Assessed under the IRIS program.|||||
2-Chlorophenol|95-57-8|Not Assessed under the IRIS program.|||||
p-Chlorophenyl methyl sulfide|123-09-1|Not Assessed under the IRIS program.|||||
p-Chlorophenyl methyl sulfone|98-57-7|Not Assessed under the IRIS program.|||||
p-Chlorophenyl methyl sulfoxide|934-73-6|Not Assessed under the IRIS program.|||||
Chloroprene|126-99-8|alveolar/ bronchiolar adenoma or carcinoma; hemangioma/ hemangiosarcoma (all organs); mammary gland adenocarcinoma, carcinoma, or adenoacanthoma; forestomach squamous cell papilloma or carcinoma; hepatocellular adenoma or carcinoma; Harderian gland adenoma or carcinoma; skin sarcoma; and Zymbal's gland carcinoma|Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.|per µg /m<sup>3</sup>|3x10<sup>-4</sup>|Inhalation|
Chlorothalonil|1897-45-6|Not Assessed under the IRIS program.|||||
o-Chlorotoluene|95-49-8|Not Assessed under the IRIS program.|||||
Chlorpropham|101-21-3|Not Assessed under the IRIS program.|||||
Chlorpyrifos|2921-88-2|Not Assessed under the IRIS program.|||||
Chlorsulfuron|64902-72-3|Not Assessed under the IRIS program.|||||
Chromium(III), insoluble salts|16065-83-1|Not Assessed under the IRIS program.|||||
Chromium(VI)|18540-29-9|Lung cancer|Multistage, extra risk|per µg /m<sup>3</sup>|1.2x10<sup>-2</sup>|Inhalation, Occupational exposure|
Chrysene|218-01-9|Not Assessed under the IRIS program.|||||
Coke oven emissions|8007-45-2|Respiratory cancer|Linearized multistage procedure|per µg /m<sup>3</sup>|6.2x10<sup>-4</sup>|Inhalation, Occupational|
Copper|7440-50-8|Not Assessed under the IRIS program.|||||
Copper cyanide|544-92-3|Not Assessed under the IRIS program.|||||
Creosote|8001-58-9|Not Assessed under the IRIS program.|||||
Crotonaldehyde|123-73-9|Not Assessed under the IRIS program.|||||
Cumene|98-82-8|Not Assessed under the IRIS program.|||||
Cyanazine|21725-46-2|Not Assessed under the IRIS program.|||||
Cyanide, free|57-12-5|Not Assessed under the IRIS program.|||||
Cyanogen|460-19-5|Not Assessed under the IRIS program.|||||
Cyanogen bromide|506-68-3|Not Assessed under the IRIS program.|||||
Cyclohexane|110-82-7|Not Assessed under the IRIS program.|||||
Cyclohexanone|108-94-1|Not Assessed under the IRIS program.|||||
Cyclohexylamine|108-91-8|Not Assessed under the IRIS program.|||||
Cyhalothrin/Karate|68085-85-8|Not Assessed under the IRIS program.|||||
Cypermethrin|52315-07-8|Not Assessed under the IRIS program.|||||
Cyromazine|66215-27-8|Not Assessed under the IRIS program.|||||
Dacthal|1861-32-1|Not Assessed under the IRIS program.|||||
Dalapon, sodium salt|75-99-0|Not Assessed under the IRIS program.|||||
Danitol|39515-41-8|Not Assessed under the IRIS program.|||||
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)|1163-19-5|Not Assessed under the IRIS program.|||||
Demeton|8065-48-3|Not Assessed under the IRIS program.|||||
Di (2-ethylhexyl)phthalate (DEHP)|117-81-7|Not Assessed under the IRIS program.|||||
Di(2-ethylhexyl)adipate|103-23-1|Not Assessed under the IRIS program.|||||
2,4-Diaminotoluene|95-80-7|Not Assessed under the IRIS program.|||||
Diazomethane|334-88-3|Not Assessed under the IRIS program.|||||
Dibenz[a,h]anthracene|53-70-3|Not Assessed under the IRIS program.|||||
Dibenzofuran|132-64-9|Not Assessed under the IRIS program.|||||
1,2-Dibromo-3-chloropropane (DBCP)|96-12-8|Not Assessed under the IRIS program.|||||
1,4-Dibromobenzene|106-37-6|Not Assessed under the IRIS program.|||||
Dibromochloromethane|124-48-1|Not Assessed under the IRIS program.|||||
Dibromodichloromethane|594-18-3|Not Assessed under the IRIS program.|||||
p,p'-Dibromodiphenyl ether|2050-47-7|Not Assessed under the IRIS program.|||||
1,2-Dibromoethane|106-93-4|Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas|Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range.|per µg /m<sup>3</sup>|6x10<sup>-4</sup>|Inhalation|
1,2-Dibromoethane|106-93-4|Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas|Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range.|per µg /m<sup>3</sup>|3x10<sup>-4</sup>|Inhalation|
Dibutyl phthalate|84-74-2|Not Assessed under the IRIS program.|||||
Dicamba|1918-00-9|Not Assessed under the IRIS program.|||||
Dichloroacetic acid|79-43-6|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
1,3-Dichlorobenzene|541-73-1|Not Assessed under the IRIS program.|||||
1,4-Dichlorobenzene|106-46-7|Not Assessed under the IRIS program.|||||
1,2-Dichlorobenzene|95-50-1|Not Assessed under the IRIS program.|||||
3,3'-Dichlorobenzidine|91-94-1|Not Assessed under the IRIS program.|||||
Dichlorodifluoromethane|75-71-8|Not Assessed under the IRIS program.|||||
p,p'-Dichlorodiphenyl dichloroethane (DDD)|72-54-8|Not Assessed under the IRIS program.|||||
p,p'-Dichlorodiphenyldichloroethylene (DDE)|72-55-9|Not Assessed under the IRIS program.|||||
p,p'-Dichlorodiphenyltrichloroethane (DDT)|50-29-3|Liver tumors, benign and malignant|Linear multistage procedure, extra risk|per µg /m<sup>3</sup>|9.7x10<sup>-5</sup>|Oral,Diet|
1,2-Dichloroethane|107-06-2|Hemangiosarcomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|2.6x10<sup>-5</sup>|Oral,Gavage|
1,1-Dichloroethane|75-34-3|Not Assessed under the IRIS program.|||||
trans-1,2-Dichloroethylene|156-60-5|Not Assessed under the IRIS program.|||||
cis-1,2-Dichloroethylene|156-59-2|Not Assessed under the IRIS program.|||||
1,1-Dichloroethylene (1,1-DCE)|75-35-4|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Dichloromethane|75-09-2|Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas|Multistage model with linear extrapolation from the point of departure (BMDL10)|per µg /m<sup>3</sup>|1x10<sup>-8</sup>|Inhalation|
2,4-Dichlorophenol|120-83-2|Not Assessed under the IRIS program.|||||
4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB)|94-82-6|Not Assessed under the IRIS program.|||||
2,4-Dichlorophenoxyacetic acid (2,4-D)|94-75-7|Not Assessed under the IRIS program.|||||
1,2-Dichloropropane|78-87-5|Not Assessed under the IRIS program.|||||
2,3-Dichloropropanol|616-23-9|Not Assessed under the IRIS program.|||||
1,3-Dichloropropene|542-75-6|Bronchioalveolar adenoma|Linearized multistage model, extra risk|per µg /m<sup>3</sup>|4x10<sup>-6</sup>|Inhalation|
Dichlorvos|62-73-7|Not Assessed under the IRIS program.|||||
Dicofol|115-32-2|Not Assessed under the IRIS program.|||||
Dieldrin|60-57-1|Liver carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|4.6x10<sup>-3</sup>|Oral, Diet|
Diesel engine exhaust|NA|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Diethyl phthalate|84-66-2|Not Assessed under the IRIS program.|||||
Diethyl sulfate|64-67-5|Not Assessed under the IRIS program.|||||
Diethyl-p-nitrophenylphosphate|311-45-5|Not Assessed under the IRIS program.|||||
Diethylene glycol dinitrate (DEGDN)|693-21-0|Not Assessed under the IRIS program.|||||
Difenzoquat|43222-48-6|Not Assessed under the IRIS program.|||||
Diflubenzuron|35367-38-5|Not Assessed under the IRIS program.|||||
1,1-Difluoroethane|75-37-6|Not Assessed under the IRIS program.|||||
Diisopropyl methylphosphonate (DIMP)|1445-75-6|Not Assessed under the IRIS program.|||||
Dimethipin|55290-64-7|Not Assessed under the IRIS program.|||||
Dimethoate|60-51-5|Not Assessed under the IRIS program.|||||
Dimethyl phthalate|131-11-3|Not Assessed under the IRIS program.|||||
Dimethyl sulfate|77-78-1|Not Assessed under the IRIS program.|||||
Dimethyl terephthalate (DMT)|120-61-6|Not Assessed under the IRIS program.|||||
Dimethylamine|124-40-3|Not Assessed under the IRIS program.|||||
N-N-Dimethylaniline|121-69-7|Not Assessed under the IRIS program.|||||
3,3-Dimethylbenzidine|119-93-7|Not Assessed under the IRIS program.|||||
N,N-Dimethylformamide|68-12-2|Not Assessed under the IRIS program.|||||
3,4-Dimethylphenol|95-65-8|Not Assessed under the IRIS program.|||||
2,6-Dimethylphenol|576-26-1|Not Assessed under the IRIS program.|||||
2,4-Dimethylphenol|105-67-9|Not Assessed under the IRIS program.|||||
4,6-Dinitro-o-cyclohexyl phenol|131-89-5|Not Assessed under the IRIS program.|||||
m-Dinitrobenzene|99-65-0|Not Assessed under the IRIS program.|||||
o-Dinitrobenzene|528-29-0|Not Assessed under the IRIS program.|||||
2,4-Dinitrophenol|51-28-5|Not Assessed under the IRIS program.|||||
2,4-Dinitrotoluene|121-14-2|Not Assessed under the IRIS program.|||||
2,4-/2,6-Dinitrotoluene mixture|NA|Not Assessed under the IRIS program.|||||
Dinoseb|88-85-7|Not Assessed under the IRIS program.|||||
1,4-Dioxane|123-91-1|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Diphenamid|957-51-7|Not Assessed under the IRIS program.|||||
Diphenylamine|122-39-4|Not Assessed under the IRIS program.|||||
1,2-Diphenylhydrazine|122-66-7|Hepatocellular carcinomas and neoplastic liver nodules|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|2.2x10<sup>-4</sup>|Oral, Diet|
Diquat|85-00-7|Not Assessed under the IRIS program.|||||
Disulfoton|298-04-4|Not Assessed under the IRIS program.|||||
1,4-Dithiane|505-29-3|Not Assessed under the IRIS program.|||||
Diuron|330-54-1|Not Assessed under the IRIS program.|||||
Dodine|2439-10-3|Not Assessed under the IRIS program.|||||
Endosulfan|115-29-7|Not Assessed under the IRIS program.|||||
Endothall|145-73-3|Not Assessed under the IRIS program.|||||
Endrin|72-20-8|Not Assessed under the IRIS program.|||||
Epichlorohydrin|106-89-8|Nasal cavity tumors|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.2x10<sup>-6</sup>|Inhalation|
1,2-Epoxybutane (EBU)|106-88-7|Not Assessed under the IRIS program.|||||
Ethephon|16672-87-0|Not Assessed under the IRIS program.|||||
Ethion|563-12-2|Not Assessed under the IRIS program.|||||
2-Ethoxyethanol|110-80-5|Not Assessed under the IRIS program.|||||
Ethyl acetate|141-78-6|Not Assessed under the IRIS program.|||||
Ethyl carbamate|51-79-6|Not Assessed under the IRIS program.|||||
Ethyl chloride|75-00-3|Not Assessed under the IRIS program.|||||
S-Ethyl dipropylthiocarbamate (EPTC)|759-94-4|Not Assessed under the IRIS program.|||||
Ethyl ether|60-29-7|Not Assessed under the IRIS program.|||||
Ethyl p-nitrophenyl phenylphosphorothioate (EPN)|2104-64-5|Not Assessed under the IRIS program.|||||
Ethylbenzene|100-41-4|Not Assessed under the IRIS program.|||||
Ethylene diamine|107-15-3|Not Assessed under the IRIS program.|||||
Ethylene glycol|107-21-1|Not Assessed under the IRIS program.|||||
Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)|111-76-2|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Ethylene thiourea (ETU)|96-45-7|Not Assessed under the IRIS program.|||||
Ethyleneimine|151-56-4|Not Assessed under the IRIS program.|||||
Ethylphthalyl ethylglycolate (EPEG)|84-72-0|Not Assessed under the IRIS program.|||||
Express|101200-48-0|Not Assessed under the IRIS program.|||||
Fenamiphos|22224-92-6|Not Assessed under the IRIS program.|||||
Fluometuron|2164-17-2|Not Assessed under the IRIS program.|||||
Fluoranthene|206-44-0|Not Assessed under the IRIS program.|||||
Fluorene|86-73-7|Not Assessed under the IRIS program.|||||
Fluorine (soluble fluoride)|7782-41-4|Not Assessed under the IRIS program.|||||
Fluridone|59756-60-4|Not Assessed under the IRIS program.|||||
Flurprimidol|56425-91-3|Not Assessed under the IRIS program.|||||
Flutolanil|66332-96-5|Not Assessed under the IRIS program.|||||
Fluvalinate|69409-94-5|Not Assessed under the IRIS program.|||||
Folpet|133-07-3|Not Assessed under the IRIS program.|||||
Fomesafen|72178-02-0|Not Assessed under the IRIS program.|||||
Fonofos|944-22-9|Not Assessed under the IRIS program.|||||
Formaldehyde|50-00-0|Squamous cell carcinoma|Linearized multistage procedure, additional risk|per µg /m<sup>3</sup>|1.3x10<sup>-5</sup>|Inhalation|
Formic acid|64-18-6|Not Assessed under the IRIS program.|||||
Fosetyl-al|39148-24-8|Not Assessed under the IRIS program.|||||
Furan|110-00-9|Not Assessed under the IRIS program.|||||
Furfural|98-01-1|Not Assessed under the IRIS program.|||||
Furmecyclox|60568-05-0|Not Assessed under the IRIS program.|||||
Glufosinate-ammonium|77182-82-2|Not Assessed under the IRIS program.|||||
Glycidaldehyde|765-34-4|Not Assessed under the IRIS program.|||||
Glyphosate|1071-83-6|Not Assessed under the IRIS program.|||||
Haloxyfop-methyl|69806-40-2|Not Assessed under the IRIS program.|||||
Harmony|79277-27-3|Not Assessed under the IRIS program.|||||
Heptachlor|76-44-8|Hepatocellular carcinomas|Linearized multistage procedure, extra risk |per µg/m<sup>3</sup>|1.3x10<sup>-3</sup>|Oral, Diet|
Heptachlor epoxide|1024-57-3|Hepatocellular carcinomas|Linearized multistage procedure, extra risk|per µg/m<sup>3</sup>|2.6x10<sup>-3</sup>|Oral, Diet|
n-Heptane|142-82-5|Not Assessed under the IRIS program.|||||
Hexabromobenzene|87-82-1|Not Assessed under the IRIS program.|||||
Hexabromodiphenyl ether|36483-60-0|Not Assessed under the IRIS program.|||||
2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)|68631-49-2|Not Assessed under the IRIS program.|||||
Hexachlorobenzene|118-74-1|Hepatocellular carcinoma|Linearized multistage, extra risk|per µg /m<sup>3</sup>|4.6x10<sup>-4</sup>|Oral, Diet|
Hexachlorobutadiene|87-68-3|Renal tubular adenomas and adenocarcinomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|2.2x10<sup>-5</sup>|Oral, Diet|
alpha-Hexachlorocyclohexane (alpha-HCH)|319-84-6|Hepatic nodules and hepatocellular carcinomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.8x10<sup>-3</sup>|Oral, Diet|
beta-Hexachlorocyclohexane (beta-HCH)|319-85-7|Hepatic nodules and hepatocellular carcinomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|5.3x10<sup>-4</sup>|Oral, Diet|
delta-Hexachlorocyclohexane (delta-HCH)|319-86-8|Not Assessed under the IRIS program.|||||
epsilon-Hexachlorocyclohexane (epsilon-HC)|6108-10-7|Not Assessed under the IRIS program.|||||
gamma-Hexachlorocyclohexane (gamma-HCH)|58-89-9|Not Assessed under the IRIS program.|||||
technical Hexachlorocyclohexane (t-HCH)|608-73-1|Liver nodules and hepatocellular carcinomas|Linearized multistage procedure|per µg /m<sup>3</sup>|5.1x10<sup>-4</sup>|Oral, Diet|
Hexachlorocyclopentadiene (HCCPD)|77-47-4|Not Assessed under the IRIS program.|||||
Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD|57653-85-7|Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas)|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.3|Oral, Gavage|
Hexachloroethane|67-72-1|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Hexachlorophene|70-30-4|Not Assessed under the IRIS program.|||||
Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)|121-82-4|Not Assessed under the IRIS program.|||||
1,6-Hexamethylene diisocyanate|822-06-0|Not Assessed under the IRIS program.|||||
n-Hexane|110-54-3|Not Assessed under the IRIS program.|||||
2-Hexanone|591-78-6|Not Assessed under the IRIS program.|||||
Hexazinone|51235-04-2|Not Assessed under the IRIS program.|||||
Hydrazine/Hydrazine sulfate|302-01-2|Nasal cavity adenoma or adenocarcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|4.9x10<sup>-3</sup>|Inhalation|
Hydrogen Cyanide and Cyanide Salts|Various|Not Assessed under the IRIS program.|||||
Hydrogen chloride|7647-01-0|Not Assessed under the IRIS program.|||||
Hydrogen sulfide|7783-06-4|Not Assessed under the IRIS program.|||||
Hydroquinone|123-31-9|Not Assessed under the IRIS program.|||||
Imazalil|35554-44-0|Not Assessed under the IRIS program.|||||
Imazaquin|81335-37-7|Not Assessed under the IRIS program.|||||
Indeno[1,2,3-cd]pyrene|193-39-5|Not Assessed under the IRIS program.|||||
Iprodione|36734-19-7|Not Assessed under the IRIS program.|||||
Isobutyl alcohol|78-83-1|Not Assessed under the IRIS program.|||||
Isophorone|78-59-1|Not Assessed under the IRIS program.|||||
Isopropalin|33820-53-0|Not Assessed under the IRIS program.|||||
Isopropyl methyl phosphonic acid (IMPA)|1832-54-8|Not Assessed under the IRIS program.|||||
Isoxaben|82558-50-7|Not Assessed under the IRIS program.|||||
Lactofen|77501-63-4|Not Assessed under the IRIS program.|||||
Lead and compounds (inorganic)|7439-92-1|Not Assessed under the IRIS program.|||||
d-Limonene|5989-27-5|Not Assessed under the IRIS program.|||||
Linuron|330-55-2|Not Assessed under the IRIS program.|||||
Londax|83055-99-6|Not Assessed under the IRIS program.|||||
Malathion|121-75-5|Not Assessed under the IRIS program.|||||
Maleic anhydride|108-31-6|Not Assessed under the IRIS program.|||||
Maleic hydrazide|123-33-1|Not Assessed under the IRIS program.|||||
Maneb|12427-38-2|Not Assessed under the IRIS program.|||||
Manganese|7439-96-5|Not Assessed under the IRIS program.|||||
Mepiquat chloride|24307-26-4|Not Assessed under the IRIS program.|||||
Mercuric chloride (HgCl2)|7487-94-7|Not Assessed under the IRIS program.|||||
Mercury, elemental|7439-97-6|Not Assessed under the IRIS program.|||||
Merphos|150-50-5|Not Assessed under the IRIS program.|||||
Merphos oxide|78-48-8|Not Assessed under the IRIS program.|||||
Metalaxyl|57837-19-1|Not Assessed under the IRIS program.|||||
Methacrylonitrile|126-98-7|Not Assessed under the IRIS program.|||||
Methamidophos|10265-92-6|Not Assessed under the IRIS program.|||||
Methanol|67-56-1|Not Assessed under the IRIS program.|||||
Methidathion|950-37-8|Not Assessed under the IRIS program.|||||
Methomyl|16752-77-5|Not Assessed under the IRIS program.|||||
Methoxychlor|72-43-5|Not Assessed under the IRIS program.|||||
2-Methoxyethanol|109-86-4|Not Assessed under the IRIS program.|||||
Methyl acrylate|96-33-3|Not Assessed under the IRIS program.|||||
Methyl chloride|74-87-3|Not Assessed under the IRIS program.|||||
Methyl chlorocarbonate|79-22-1|Not Assessed under the IRIS program.|||||
Methyl ethyl ketone (MEK)|78-93-3|Not Assessed under the IRIS program.|||||
Methyl iodide|74-88-4|Not Assessed under the IRIS program.|||||
Methyl isobutyl ketone (MIBK)|108-10-1|Not Assessed under the IRIS program.|||||
Methyl isocyanate|624-83-9|Not Assessed under the IRIS program.|||||
Methyl methacrylate|80-62-6|Not Assessed under the IRIS program.|||||
Methyl parathion|298-00-0|Not Assessed under the IRIS program.|||||
Methyl tert-butyl ether (MTBE)|1634-04-4|Not Assessed under the IRIS program.|||||
4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB)|94-81-5|Not Assessed under the IRIS program.|||||
2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP)|93-65-2|Not Assessed under the IRIS program.|||||
2-Methyl-4-chlorophenoxyacetic acid (MCPA)|94-74-6|Not Assessed under the IRIS program.|||||
Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)|101-68-8|Not Assessed under the IRIS program.|||||
4,4'-Methylene bis(N,N'-dimethyl)aniline|101-61-1|Not Assessed under the IRIS program.|||||
Methylmercury (MeHg)|22967-92-6|Not Assessed under the IRIS program.|||||
2-Methylnaphthalene|91-57-6|Not Assessed under the IRIS program.|||||
2-Methylphenol|95-48-7|Not Assessed under the IRIS program.|||||
4-Methylphenol|106-44-5|Not Assessed under the IRIS program.|||||
3-Methylphenol|108-39-4|Not Assessed under the IRIS program.|||||
Metolachlor|51218-45-2|Not Assessed under the IRIS program.|||||
Metribuzin|21087-64-9|Not Assessed under the IRIS program.|||||
Mirex|2385-85-5|Not Assessed under the IRIS program.|||||
Molinate|2212-67-1|Not Assessed under the IRIS program.|||||
Molybdenum|7439-98-7|Not Assessed under the IRIS program.|||||
Monochloramine|10599-90-3|Not Assessed under the IRIS program.|||||
Naled|300-76-5|Not Assessed under the IRIS program.|||||
Naphthalene|91-20-3|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Napropamide|15299-99-7|Not Assessed under the IRIS program.|||||
Nickel carbonyl|13463-39-3|Not Assessed under the IRIS program.|||||
Nickel refinery dust|NA|Lung cancer|Additive and multiplicative|per µg /m<sup>3</sup>|2.4x10-4|Inhalation|
Nickel subsulfide|12035-72-2|Lung cancer|Additive and multiplicative|per µg /m<sup>3</sup>|4.8x10<sup>-4</sup>|Inhalation|
Nickel, soluble salts|NA|Not Assessed under the IRIS program.|||||
Nitrapyrin|1929-82-4|Not Assessed under the IRIS program.|||||
Nitrate|14797-55-8|Not Assessed under the IRIS program.|||||
Nitric oxide|10102-43-9|Not Assessed under the IRIS program.|||||
Nitrite|14797-65-0|Not Assessed under the IRIS program.|||||
Nitrobenzene|98-95-3|Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas|Multistage model with linear extrapolation from the POD (LEC10).|per µg /m<sup>3</sup>|4x10<sup>-5</sup>|Inhalation|
Nitrogen dioxide|10102-44-0|Not Assessed under the IRIS program.|||||
Nitroguanidine|556-88-7|Not Assessed under the IRIS program.|||||
p-Nitrophenol|100-02-7|Not Assessed under the IRIS program.|||||
2-Nitropropane|79-46-9|Not Assessed under the IRIS program.|||||
N-Nitroso-N-methylethylamine|10595-95-6|Not Assessed under the IRIS program.|||||
N-Nitroso-di-n-butylamine|924-16-3|Bladder and esophagus tumors|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.6x10<sup>-3</sup>|Oral, Drinking water|
N-Nitrosodi-N-propylamine|621-64-7|Not Assessed under the IRIS program.|||||
N-Nitrosodiethanolamine|1116-54-7|Not Assessed under the IRIS program.|||||
N-Nitrosodiethylamine|55-18-5|Liver tumors|Weibull, extra risk|per µg /m<sup>3</sup>|4.3x10<sup>-2</sup>|Oral, Drinking water|
N-Nitrosodimethylamine|62-75-9|Liver tumors|Weibull, extra risk|per µg /m<sup>3</sup>|1.4x10<sup>-2</sup>|Oral, Drinking water|
N-Nitrosodiphenylamine|86-30-6|Not Assessed under the IRIS program.|||||
N-Nitrosopyrrolidine|930-55-2|Hepatocellular carcinoma and adenoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|6.1x10<sup>-4</sup>|Oral, Diet|
Nonabromodiphenyl ether|63936-56-1|Not Assessed under the IRIS program.|||||
Norflurazon|27314-13-2|Not Assessed under the IRIS program.|||||
NuStar|85509-19-9|Not Assessed under the IRIS program.|||||
Octabromodiphenyl ether|32536-52-0|Not Assessed under the IRIS program.|||||
Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX)|2691-41-0|Not Assessed under the IRIS program.|||||
Oryzalin|19044-88-3|Not Assessed under the IRIS program.|||||
Oxadiazon|19666-30-9|Not Assessed under the IRIS program.|||||
Oxamyl|23135-22-0|Not Assessed under the IRIS program.|||||
Oxyfluorfen|42874-03-3|Not Assessed under the IRIS program.|||||
Paclobutrazol|76738-62-0|Not Assessed under the IRIS program.|||||
Paraquat|1910-42-5|Not Assessed under the IRIS program.|||||
Parathion|56-38-2|Not Assessed under the IRIS program.|||||
Pendimethalin|40487-42-1|Not Assessed under the IRIS program.|||||
Pentabromodiphenyl ether|32534-81-9|Not Assessed under the IRIS program.|||||
2,2',4,4',5-Pentabromodiphenyl ether (BDE-99)|60348-60-9|Not Assessed under the IRIS program.|||||
Pentachlorobenzene|608-93-5|Not Assessed under the IRIS program.|||||
Pentachlorocyclopentadiene|25329-35-5|Not Assessed under the IRIS program.|||||
Pentachloronitrobenzene (PCNB)|82-68-8|Not Assessed under the IRIS program.|||||
Pentachlorophenol|87-86-5|Not Assessed under the IRIS program.|||||
Pentafluoroethane|354-33-6|Not Assessed under the IRIS program.|||||
Perchlorate (ClO4) and Perchlorate Salts|7790-98-9|Not Assessed under the IRIS program.|||||
Permethrin|52645-53-1|Not Assessed under the IRIS program.|||||
Phenanthrene|85-01-8|Not Assessed under the IRIS program.|||||
Phenmedipham|13684-63-4|Not Assessed under the IRIS program.|||||
Phenol|108-95-2|Not Assessed under the IRIS program.|||||
m-Phenylenediamine|108-45-2|Not Assessed under the IRIS program.|||||
Phenylmercuric acetate|62-38-4|Not Assessed under the IRIS program.|||||
Phosalone|2310-17-0|Not Assessed under the IRIS program.|||||
Phosgene|75-44-5|Not Assessed under the IRIS program.|||||
Phosmet|732-11-6|Not Assessed under the IRIS program.|||||
Phosphine|7803-51-2|Not Assessed under the IRIS program.|||||
Phosphoric acid|7664-38-2|Not Assessed under the IRIS program.|||||
Phthalic anhydride|85-44-9|Not Assessed under the IRIS program.|||||
Picloram|1918-02-1|Not Assessed under the IRIS program.|||||
Pirimiphos-methyl|29232-93-7|Not Assessed under the IRIS program.|||||
Polychlorinated biphenyls (PCBs)|1336-36-3|Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas|Linear extrapolation below LED10s|per µg /m<sup>3</sup>|1x10<sup>-4</sup>|Oral, Diet|
Potassium cyanide|151-50-8|Not Assessed under the IRIS program.|||||
Potassium silver cyanide|506-61-6|Not Assessed under the IRIS program.|||||
Prochloraz|67747-09-5|Not Assessed under the IRIS program.|||||
Prometon|1610-18-0|Not Assessed under the IRIS program.|||||
Prometryn|7287-19-6|Not Assessed under the IRIS program.|||||
Pronamide|23950-58-5|Not Assessed under the IRIS program.|||||
Propachlor|1918-16-7|Not Assessed under the IRIS program.|||||
Propanil|709-98-8|Not Assessed under the IRIS program.|||||
Propargite|2312-35-8|Not Assessed under the IRIS program.|||||
Propargyl alcohol|107-19-7|Not Assessed under the IRIS program.|||||
Propazine|139-40-2|Not Assessed under the IRIS program.|||||
Propham|122-42-9|Not Assessed under the IRIS program.|||||
Propiconazole|60207-90-1|Not Assessed under the IRIS program.|||||
beta-Propiolactone|57-57-8|Not Assessed under the IRIS program.|||||
Propionaldehyde|123-38-6|Not Assessed under the IRIS program.|||||
Propylene glycol|57-55-6|Not Assessed under the IRIS program.|||||
Propylene glycol monoethyl ether|52125-53-8|Not Assessed under the IRIS program.|||||
Propylene glycol monomethyl ether (PGME)|107-98-2|Not Assessed under the IRIS program.|||||
Propylene oxide|75-56-9|Nasal cavity hemangioma or hemangiosarcoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.7x10<sup>-6</sup>|Inhalation|
Propyleneimine|75-55-8|Not Assessed under the IRIS program.|||||
Pursuit|81335-77-5|Not Assessed under the IRIS program.|||||
Pydrin|51630-58-1|Not Assessed under the IRIS program.|||||
Pyrene|129-00-0|Not Assessed under the IRIS program.|||||
Pyridine|110-86-1|Not Assessed under the IRIS program.|||||
Quinalphos|13593-03-8|Not Assessed under the IRIS program.|||||
Quinoline|91-22-5|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Quinone|106-51-4|Not Assessed under the IRIS program.|||||
Radium 226,228|7440-14-4|Not Assessed under the IRIS program.|||||
Radon 222|14859-67-7|Not Assessed under the IRIS program.|||||
Refractory ceramic fibers|NA|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Resmethrin|10453-86-8|Not Assessed under the IRIS program.|||||
Rotenone|83-79-4|Not Assessed under the IRIS program.|||||
Savey|78587-05-0|Not Assessed under the IRIS program.|||||
Selenious acid|7783-00-8|Not Assessed under the IRIS program.|||||
Selenium and Compounds|7782-49-2|Not Assessed under the IRIS program.|||||
Selenium sulfide|7446-34-6|Not Assessed under the IRIS program.|||||
Selenourea|630-10-4|Not Assessed under the IRIS program.|||||
Sethoxydim|74051-80-2|Not Assessed under the IRIS program.|||||
Silver|7440-22-4|Not Assessed under the IRIS program.|||||
Silver cyanide|506-64-9|Not Assessed under the IRIS program.|||||
Simazine|122-34-9|Not Assessed under the IRIS program.|||||
Sodium azide|26628-22-8|Not Assessed under the IRIS program.|||||
Sodium cyanide|143-33-9|Not Assessed under the IRIS program.|||||
Sodium diethyldithiocarbamate|148-18-5|Not Assessed under the IRIS program.|||||
Sodium fluoroacetate|62-74-8|Not Assessed under the IRIS program.|||||
Strontium|7440-24-6|Not Assessed under the IRIS program.|||||
Strychnine|57-24-9|Not Assessed under the IRIS program.|||||
Styrene|100-42-5|Not Assessed under the IRIS program.|||||
Systhane|88671-89-0|Not Assessed under the IRIS program.|||||
Tebuthiuron|34014-18-1|Not Assessed under the IRIS program.|||||
Terbacil|5902-51-2|Not Assessed under the IRIS program.|||||
Terbutryn|886-50-0|Not Assessed under the IRIS program.|||||
Tetrabromodiphenyl ether|40088-47-9|Not Assessed under the IRIS program.|||||
2,2',4,4'-Tetrabromodiphenyl ether (BDE-47)|5436-43-1|Not Assessed under the IRIS program.|||||
1,2,4,5-Tetrachlorobenzene|95-94-3|Not Assessed under the IRIS program.|||||
Tetrachlorocyclopentadiene|695-77-2|Not Assessed under the IRIS program.|||||
1,1,1,2-Tetrachloroethane|630-20-6|Hepatocellular adenoma or carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|7.4x10<sup>-6</sup>|Oral, Gavage|
1,1,2,2-Tetrachloroethane|79-34-5|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Tetrachloroethylene|127-18-4|Not Assessed under the IRIS program.|||||
2,3,4,6-Tetrachlorophenol|58-90-2|Not Assessed under the IRIS program.|||||
Tetrachlorovinphos|961-11-5|Not Assessed under the IRIS program.|||||
Tetraethyl lead|78-00-2|Not Assessed under the IRIS program.|||||
Tetraethyldithiopyrophosphate|3689-24-5|Not Assessed under the IRIS program.|||||
1,1,1,2-Tetrafluoroethane|811-97-2|Not Assessed under the IRIS program.|||||
Thallium (I), soluble salts|Various|Not Assessed under the IRIS program.|||||
Thallium acetate|563-68-8|Not Assessed under the IRIS program.|||||
Thallium carbonate|6533-73-9|Not Assessed under the IRIS program.|||||
Thallium chloride|7791-12-0|Not Assessed under the IRIS program.|||||
Thallium nitrate|10102-45-1|Not Assessed under the IRIS program.|||||
Thallium oxide|1314-32-5|Not Assessed under the IRIS program.|||||
Thallium selenite|12039-52-0|Not Assessed under the IRIS program.|||||
Thallium(I) sulfate|7446-18-6|Not Assessed under the IRIS program.|||||
Thiobencarb|28249-77-6|Not Assessed under the IRIS program.|||||
Thiophanate-methyl|23564-05-8|Not Assessed under the IRIS program.|||||
Thiram|137-26-8|Not Assessed under the IRIS program.|||||
Toluene|108-88-3|Not Assessed under the IRIS program.|||||
2,4-/2,6-Toluene diisocyanate mixture (TDI)|26471-62-5|Not Assessed under the IRIS program.|||||
Toxaphene|8001-35-2|Hepatocellular carcinomas and neoplastic nodules|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.2x10<sup>-4</sup>|Oral, Diet|
Tralomethrin|66841-25-6|Not Assessed under the IRIS program.|||||
Triallate|2303-17-5|Not Assessed under the IRIS program.|||||
Triasulfuron|82097-50-5|Not Assessed under the IRIS program.|||||
1,2,4-Tribromobenzene|615-54-3|Not Assessed under the IRIS program.|||||
Tribromochloromethane|594-15-0|Not Assessed under the IRIS program.|||||
Tribromodiphenyl ether|49690-94-0|Not Assessed under the IRIS program.|||||
Tributyltin oxide (TBTO)|56-35-9|Not Assessed under the IRIS program.|||||
1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113)|76-13-1|Not Assessed under the IRIS program.|||||
Trichloroacetic acid|76-03-9|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
1,2,4-Trichlorobenzene|120-82-1|Not Assessed under the IRIS program.|||||
Trichlorocyclopentadiene|77323-84-3|Not Assessed under the IRIS program.|||||
1,1,2-Trichloroethane|79-00-5|Hepatocellular carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.6x10<sup>-5</sup>|Oral, Gavage|
1,1,1-Trichloroethane|71-55-6|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Trichloroethylene|79-01-6|Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors|Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk|per µg /m<sup>3</sup>|4.1x10<sup>-6</sup>|Inhalation|
Trichlorofluoromethane|75-69-4|Not Assessed under the IRIS program.|||||
2,4,5-Trichlorophenol|95-95-4|Not Assessed under the IRIS program.|||||
2,4,6-Trichlorophenol|88-06-2|Leukemia|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.1x10<sup>-6</sup>|Oral,Diet|
2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP)|93-72-1|Not Assessed under the IRIS program.|||||
2,4,5-Trichlorophenoxyacetic acid (2,4,5-T)|93-76-5|Not Assessed under the IRIS program.|||||
1,1,2-Trichloropropane|598-77-6|Not Assessed under the IRIS program.|||||
1,2,3-Trichloropropane|96-18-4|Not Assessed under the IRIS program.|||||
Tricresol|1319-77-3|Not Assessed under the IRIS program.|||||
Tridiphane|58138-08-2|Not Assessed under the IRIS program.|||||
Triethylamine|121-44-8|Not Assessed under the IRIS program.|||||
Triethylene glycol monobutyl ether|143-22-6|Not Assessed under the IRIS program.|||||
Triethylene glycol monoethyl ether|112-50-5|Not Assessed under the IRIS program.|||||
Trifluralin|1582-09-8|Not Assessed under the IRIS program.|||||
2,2,4-Trimethylpentane|540-84-1|Not Assessed under the IRIS program.|||||
1,3,5-Trinitrobenzene|99-35-4|Not Assessed under the IRIS program.|||||
2,4,6-Trinitrotoluene (TNT)|118-96-7|Not Assessed under the IRIS program.|||||
Uranium, natural|7440-61-1|Not Assessed under the IRIS program.|||||
Uranium, soluble salts|NA|Not Assessed under the IRIS program.|||||
Urea|57-13-6|Not Assessed under the IRIS program.|||||
Vanadium pentoxide|1314-62-1|Not Assessed under the IRIS program.|||||
Vernam|1929-77-7|Not Assessed under the IRIS program.|||||
Vinclozolin|50471-44-8|Not Assessed under the IRIS program.|||||
Vinyl acetate|108-05-4|Not Assessed under the IRIS program.|||||
Vinyl bromide|593-60-2|Not Assessed under the IRIS program.|||||
Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LMS method|per µg /m<sup>3</sup>|4.4x10<sup>-6</sup>|Inhalation|
Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LED 10/ linear method|per µg /m<sup>3</sup>|4.4x10<sup>-6</sup>|Inhalation|
Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LMS method|per µg /m<sup>3</sup>|8.8x10<sup>-6</sup>|Inhalation|
Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LED 10/ linear method|per µg /m<sup>3</sup>|8.8x10<sup>-6</sup>|Inhalation|
Warfarin|81-81-2|Not Assessed under the IRIS program.|||||
White phosphorus|7723-14-0|Not Assessed under the IRIS program.|||||
Xylenes|1330-20-7|Not Assessed under the IRIS program.|||||
Zinc and Compounds|7440-66-6|Not Assessed under the IRIS program.|||||
Zinc cyanide|557-21-1|Not Assessed under the IRIS program.|||||
Zinc phosphide|1314-84-7|Not Assessed under the IRIS program.|||||
Zineb|12122-67-7|Not Assessed under the IRIS program.|||||
</t2b>


==References==
==References==

Latest revision as of 13:02, 11 March 2014

This page provides a description and a link to a "IRIS" database that provides information needed when modeling exposure levels or performing exposure assessment.

Short description

IRIS is a database of human health effects that may result from exposure to various substances found in the environment. The heart of the IRIS system is its collection of computer files covering individual chemicals. These chemical files contain descriptive and quantitative information in the following categories: a) Oral reference doses and inhalation reference concentrations (RfDs and RfCs, respectively) for chronic noncarcinogenic health effects, b) Hazard identification, oral slope factors, and oral and inhalation unit risks for carcinogenic effects. Database includes over 500 chemicals.

Long description

http://www.nlm.nih.gov/pubs/factsheets/irisfs.html

Link

http://www.epa.gov/iris/

Key words

human health effects, exposure, toxicology, carcinogenity, hazards

Data scrapping

IRIS database is accessible from this link: http://cfpub.epa.gov/ncea/iris/compare.cfm. The critical data can be obtained at once if all substances and all types of data are selected. A result is an html file with several tables from which the data can be scrapped and transformed into a better format. The January 4th, 2012, version was downloaded from IRIS and saved on this page (see the file below). Who could do this?

Reference system in IRIS database. The number (e.g. 0442) refers to the IRIS chemical identifier. 

QuickView
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal  Oral RfDs
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#refinhal Inhalation RfCs
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#woe      Weight-of-Evidence Characterizations
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quaoral  Oral Slope Factors/Drinking Water Unit Risks
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quainhal Inhalation Unit Risks

IRIS Summary 
http://www.epa.gov/iris/subst/0442.htm#reforal
http://www.epa.gov/iris/subst/0442.htm#refinhal
http://www.epa.gov/iris/subst/0442.htm#woe
http://www.epa.gov/iris/subst/0442.htm#quaoral
http://www.epa.gov/iris/subst/0442.htm#quainhal

Toxicological Review (PDF)
http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)

←--#: . Tämähän alkaa olla oikein hyvä! Alla vielä muutamia kommentteja. --Jouni 20:34, 28 June 2012 (EEST) (type: truth; paradigms: science: defence)

  • Tulokset on tässä kirjoitettu muotoon 3.4x10-3. Joko interpret-funktiota on päivitettävä siten, että se ymmärtää tämän, tai sitten kaikki näiden taulukoiden tulokset pitää muuttaa muotoon 3.4e-3 (jonka R ymmärtää oikein, kun käytetään as.numericia). Tuntuu, että interpretin päivitys olisi parempi vaihtoehto.
  • Yksiköt pitäisi muuttaa tietokoneelle ymmärrettäväksi. Vaihtoehtoja: a) Unit conversions -sivulle lisätään kaikki tässä esiintyvät uudet yksiköt, niin että niille saadaan muunnosohjeet (esim. mg /kg-day → mg /kg /d tai per µg /m3 → m3 /µg. b) Kaikki yksiköt tällä sivulla muutetaan tuohon standardimuotoon. Mikä tuntuisi järkevältä?


⇤--#: . Jos jossakin taulukossa joka rivillä on sama yksikkö, koko saraketta ei tarvita vaan riittää yksikön ilmoittaminen osoiterivillä. --Jouni 20:34, 28 June 2012 (EEST) (type: truth; paradigms: science: attack)

⇤--#: . Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä. --Jouni 10:42, 20 June 2012 (EEST) (type: truth; paradigms: science: attack)

⇤--#: . Huomaa, että IRIS identifier on tärkeä. Se löytyy nettilinkeistä (esim. Acenaphthenen QuickView on tämmöinen linkki: http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal ja siitä näkee, että tämän aineen IRIS identifier on 0442. --Jouni 10:42, 20 June 2012 (EEST) (type: truth; paradigms: science: attack)

See also

References


Related files

<mfanonymousfilelist></mfanonymousfilelist>

Retrieved from "https://en.opasnet.org/index.php?title=IRIS&oldid=31668"